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Mucosal transmission of HIV is a complex, inefficient event that leads to the seeding, 
and eventual disruption, of the gut-associated lymphoid tissue. The basis for the gut-tropic 
nature of acute HIV infection is unknown. The HIV envelope protein (Env) of early-
replicating viruses encode several distinct transmission signatures believed to impart 
increased transmission fitness on these isolates. One such signature involves a reduced 
number of potential N-linked glycosylation sites underscoring the importance of 
glycosylation on the fitness of early-replicating isolates. Our group has previously shown 
that Env glycosylation plays a role in the interaction between the V2 domain of Env gp120 
(V2) and the gut homing receptor, integrin α4β7, expressed on HIV target CD4+ T-cells. 
The α4β7 binding epitope on the V2 overlaps with the RV144 Thailand HIV vaccine trial 
sieve residues associated with vaccine-elicited immune pressure. In this thesis, we present 
data showing that a second signature of transmission located in the signal peptide (SP) of 
Env can modulate the antigenicity of gp120 and influence viral neutralization sensitivity 
through altered glycan processing. Additionally, we show that deglycosylation of gp120 
can increase the functional capacity of α4β7 adhesion to the V2. We also show that mAbs 
from vaccination and natural infection targeting an alternate, helical conformation of the 
V2 that is absent from the SOSIP stabilized trimer inhibit the adhesion of α4β7 expressing 
cells to V2 peptides. This conformation of the V2 is present on incompletely-processed 
Env that is expressed on the surface of infected cells and is incorporated into virions. This 
data suggests that incompletely-processed Env presents the V2 in an unconstrained, helical 
conformation that is capable of binding α4β7. Taken together, the data presented in this 
thesis suggests a mechanism by which the virus can modulate glycosylation of the Env 
 iii 
protein without changing the primary amino acid sequence of the functional protein, and 
that relevant, incompletely-processed Env exposes the α4β7 binding site on V2. This data 
supports the connection between Env glycosylation, the gut homing integrin α4β7 and the 
transmission and pathogenesis of HIV. We believe this data is useful for HIV vaccine and 
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1.1 Historical Context of the HIV Epidemic 
 
In 1981, physicians in Los Angeles and New York began reporting clusters of cases 
presenting with previously rare lung infections (Pneumocystis carinii pneumonia) and 
unusually aggressive cancer (Kaposi’s Sarcoma) in predominantly young men who have 
sex with men (MSM) [1, 2]. Survival of less than 20 months was reported for these patients, 
rather than the expected 8-13 years with such diagnoses. By the end of the year, a total of 
270 cases of severe immune deficiency had been reported in MSM, 121 of which had died 
[3]. In 1982, the US Centers for Disease Control used the term AIDS, acquired immune 
deficiency syndrome, for the first time to describe this disorder of cellular immunity. In 
1983, Francoise Barre-Sinoussi and Luc Montagnier at the Pasteur Institute published a 
report citing the isolation of a T-lymphotropic retrovirus and its potential as the causative 
agent for AIDS [4]. The following year, four articles all published in the same issue of 
Science by Robert Gallo and colleagues reported extensively on 1) the detection, isolation 
and production of what they designated HTLV-III from symptomatic AIDS patients, 2) the 
ability to frequently detect and isolate HTLV-III from AIDS and pre-AIDS patients, 3) the 
characterization of HTLV-III as a distinct relative of the other HTLV family members, and 
4) the presence of HTLV-III-reactive antibodies in the serum of AIDS and pre-AIDS 
patients [5-8]. In 1986, HTLV-III was officially renamed HIV (human immunodeficiency 
virus). That same year, cases of HIV/AIDS had reached every major region of the world 
with a total of over 38,000 cases worldwide.  
It wasn’t until 1990 that the US FDA approved the first drug, zidovudine (AZT), to 
treat children with AIDS. By then, the infection had exploded globally to an estimated 8-
10 million people living with HIV and over 300,000 documented cases of AIDS [9]. The 
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FDA approved Combivir in 1997, the first combination antiretroviral therapy (ART) to 
treat HIV infection. It wasn’t until 2011 that the FDA approved the second all-in-one 
combination therapy option for people living with HIV. In 2012 the FDA approved PrEP, 
pre-exposure prophylaxis, for HIV-negative, at-risk individuals to prevent sexual 
transmission of HIV with the aim of reducing transmission by providing anti-retroviral 
therapy as a prevention therapy. With the aim of reducing transmission further, the WHO 
launched new treatment guidelines in 2015 recommending that all people living with HIV 
should receive antiretroviral therapy as soon as possible after their diagnosis, regardless of 
their CD4+ T-cell count. Previously, people living with HIV were not put on therapy until 
they experienced a drop in CD4+ T-cell count, leaving the chance that a viremic individual 
could transmit the virus to a partner. Subsequent studies of HIV discordant couples (HPTN 
052 and PARTNER) showed that HIV transmission from people living with HIV that are 
virally suppressed by ART to undetectable levels is virtually zero [10, 11]. This finding 
has led to the adoption of the educational and anti-stigma slogan “U=U” (undetectable = 
untransmittable), meaning that a person living with HIV who is virally suppressed by ART 
to an undetectable viral load does not transmit the virus to their partners.  
Even with the development of combination ART and transmission prevention 
strategies, the epidemic continues. In 2017, there was an estimated 36.7 million people 
living with HIV/AIDS worldwide, including 2.1 million children less than 15 years old. 
Every year an estimated 1.8 million individuals become newly infected – about 5,000 new 
infections every day. Unfortunately, only an estimated 70% of people living with HIV 
know their status, highlighting a gap in access to testing services. Additionally, only 20.9 
million out of the estimated 36.7 million people living with HIV (~57%) are accessing 
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ART. Gaps in access to testing and treatment highlight the importance of developing an 
effective, robustly protective HIV vaccine.  
Since the onset of the HIV epidemic there have been over 220 Phase I, II and III 
HIV vaccine clinical trials, a majority of which (140 trials) were conducted in the US [12]. 
Only 6 clinical HIV vaccine trials made it to vaccine efficacy testing [13]. These trials 
tested a number of vaccine components and regimens; using different HIV proteins, vectors 
and boosting schedules. The first wave of vaccine trials was focused on inducing 
neutralizing antibodies, which for other infectious diseases has proven successful. 
Unfortunately, no vaccine to date has been able to elicit broadly neutralizing antibodies 
that provide protection from HIV transmission. Due to failures in this approach, the second 
wave of vaccine trials focused on inducing cell-mediated immunity with the hope that a 
vaccine induced cellular response could block infection. The debate over which of these 
two approaches should be prioritized continues today. The current phase of vaccine design 
attempts to induce multiple immune responses with the purpose of potentially providing 
protection through a combination of responses. To date, out of the scores of trials 
conducted, the RV144 Thailand HIV vaccine trial is the only trial with any measurable 
reduction in risk of infection - 31.2% vaccine efficacy [14]. Moderate efficacy is not ideal. 
However, immune correlate studies from RV144 have provided insights into potential 
mechanisms of reduced risk of acquisition. RV144 and its subsequent analyses are 
discussed in great detail throughout this thesis as they shape the field’s current foundation 
for correlates of immunity.  
 
1.2 Mucosal Transmission and the Early Events of HIV Infection 
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Mucosal transmission of HIV involves a complex yet strikingly inefficient series 
of events that are not yet fully understood [15, 16]. Much of this complexity is due to the 
natural variability found in several fundamental characteristics of HIV. The field of HIV 
research has long sought to understand these variabilities to trace the evolutionary history 
of the virus, track demographic trends in the epidemic, and more importantly, develop 
effective therapies and prevention strategies to control the spread of infection.  
One key variability in HIV is its vast genetic diversity (Figure 1.1). In order to 
organize the evolutionary and sequence differences of the major M group of HIV-1, 
isolates have been classified into subtypes based on phylogenetic similarity of their genome 
sequences. The major subtype groups are labeled with letters: A1, A2, A3, A4, A6, B, C, 
D, F1, F2, G, H, J, and K. More complete genome sequencing of the subtypes led to the 
identification of prevalent inter-subtype recombination events accompanied by the 
establishment of additional classifications termed circulating recombinant forms (CRFs). 
These mosaic CRF genomes are labeled with numbers followed by the parental subtype 
letters that are believed to contribute to their genome (i.e. CRF02_AG, CRF05_DF and 
CRF01_AE). Each subtype and CRF is characterized by a reference isolate genome 
sequence and at least three other non-epidemiologically related isolates. The major subtype 
groups and CRFs often have geographic associations in that some subtypes and CRFs are 
more prevalent in specific countries or regions than in others. This diversity in sequence 
across the globe has been a major obstacle to global HIV vaccine design. Some in the field 
have proposed the potential for subtype- or geographic- specific vaccine development to 
narrow the scope of protection.  However, the feasibility and practicality of this method is 
still under debate.   
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Figure 1.1. Genetic diversity of HIV in an individual and in a country. (A) The 
genetic diversity of HIV isolates replicating in a chronically HIV infected individual 
as measured by phylogenic analysis of Env sequence is similar to (B) the genetic 
diversity of Influenza replicating worldwide for a given year (1997). (C) The genetic 
diversity of HIV replicating in an entire country during a given year (1997) is several-
fold larger than that of an individual. Scale bar is the same for all trees. Adapted from 
Korber et al. [17].     
 
Another variability that adds to the complexity of HIV transmission involves the 
genetic diversity within an individual chronically living with HIV. Regardless of HIV 
subtype, in a chronically HIV infected individual there exists a genetically diverse 
population of quasi-species of replicating virus. This sequence diversity arises from HIV’s 
error prone reverse transcriptase enzyme (RT), an RNA-dependent DNA polymerase that 
lacks an effective proofreading mechanism. The high mutation rate of HIV RT, coupled 
with the virus’s rapid replication, is the driver of not only sequence diversity in an infected 
individual but also the genetic diversity observed in populations across the globe. 
Additionally, the HIV genome is subject to recombination events, or large insertions and 
deletions, and of course, significant immune pressure from the host. These agents all add 
to the complexity in which vast genetic diversity of HIV is achieved.  
Despite the existence of multiple genetically diverse isolates replicating in an HIV 
infected individual, very often, at the time of HIV transmission, only a single or very few 
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genetically distinct “founder” isolates is able to establish a productive infection in a 
recipient (Figure 1.2). Studies of natural HIV transmission have shown that despite vast 
heterogeneity in the donor preceding transmission, extreme sequence restriction leads to 
nearly homogeneous viral sequences in the recipient. This genetic bottleneck is the result 
of extreme selective pressure against the virus as it leaves the donor and makes its way 
through the genital mucosa of the recipient to establish infection. Sequence analyses from 
transmission events among discordant heterosexual couples shows that in roughly 80% of 
individuals tested, only a single viral isolate is transmitted [18-20]. SIV and SHIV 
transmission studies (non-human primate models for HIV) have also shown that infection 
with a heterogeneous viral stock leads to one or very few isolates establishing infection. 
That HIV reproducibly goes through cycles of genetic restriction during transmission 
suggests that the barrier to transmission is quite high and that the efficiency of transmission 
is low.     
The existence of such a severe genetic bottleneck during HIV transmission suggests 
that transmission of HIV is also extremely inefficient. In fact, studies of monogamous 
couples in the Rakai district of Uganda that are discordant for HIV show that productive 
infection of the HIV negative partner occurred from roughly 1 in 1000 coital acts [15]. This 
study also showed that the risk of HIV transmission is increased during the first 2.5 months 
after acquisition, when the virus is replicating at extremely high levels [16]. This study and 
others suggest that while there are high levels of replication throughout the length of HIV 
infection, barriers exist that make transmission inefficient. This barrier of transmission 




Figure 1.2. Genetic Bottleneck During Mucosal HIV Transmission. In an HIV 
infected individual, there exists a replicating population of genetically diverse quasi-
species of virus. During mucosal transmission, this swarm undergoes extreme 
restriction crossing the mucosal barrier such that only a single, genetically distinct 
(Blue virion), or very few isolates, establish a productive infection in the recipient.   
 
Immediately following a transmission event, the virus begins replicating in target 
cells of the newly infected individual. Clinical characterizations are used to classify the 
progression of the early stages of HIV infection (Figure 1.3). The first stage following 
transmission is known as the eclipse phase, where viral RNA and protein are undetectable 
in the blood. This phase has historically been characterized to last seven to ten days. With 
the development of ultra-sensitive detection assays, viral RNA can now be detected in 
blood within the first 3-5 days after transmission. During the eclipse phase, viral RNA 
levels in the blood grow exponentially due to rapid viral replication in CD4+ T-cells. After 
viral RNA becomes detectable in the blood, the infection is considered to be in Fiebig stage 
1. This stage continues until the viral protein p24 can be detected in blood, which usually 
occurs around 15 to 18 days after transmission. During this time, the CD4+ T-cell count, 
which in healthy, uninfected individuals is ~1000 cells/mm3, declines rapidly to ≤500 
cells/mm3. This destruction of immune cells leads to flu-like symptoms (fever, chills, 
fatigue, headache, sore throat, etc.), although not in all cases. Fiebig stage 3 follows and is 
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characterized by detection of anti-HIV antibodies in the blood. The detection of antiviral 
antibodies in the blood indicates that the immune system is attempting to combat the 
infection through adaptive immune pressure. As immune pressure builds against the 
transmitting isolate early in infection, selection for minor variants or newly acquired 
mutations takes place. This game of ‘cat and mouse’ in which the immune system is 
chasing a rapid, ever-changing target while the virus is depleting a significant fraction of 
immune cells leads to the destruction of critical host immune barriers and the eventual 
development of AIDS.  
 
Figure 1.3. Stages of HIV infection classified by viremia and CD4+ T-cell count. 
Schematic of viral load (left y-axis) and CD4 lymphocyte count (right y-axis) over 
time (x-axis) of HIV infection. The early/acute phase of infection is classified into 
stages of clinical diagnostics (Fiebig stages).   
 
Acute HIV infection is characterized by significant replication in and subsequent 
depletion of CD4+ T-cells, particularly of the gut associated lymphoid tissue (GALT). The 
GALT has the largest surface area of all organs, and because the GALT comes into direct 
contact with a hostile external environment, it therefore contains a large population of 
protective immune cells. The GALT harbors some ~50% of the body’s CD4+ T-cell 
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population. During HIV infection, the CD4+ T-cell population can be cut in half as a result 
of viral replication and targeted cell killing. Irreversible damage to the GALT is associated 
with the loss of mucosal barrier maintenance that protects the gut tissue from pathogens, 
as well as the digestive and metabolic functions of the gut. This gut-tropic nature of HIV 
infection is not completely understood, although this topic is introduced in section 1.5 
further and discussed throughout this thesis.  
While HIV can enter both activated and nonactivated target cells, the virus requires 
cellular activation for high levels of replication to take place. Highly activated cells are 
therefore ideal targets for HIV infection. A major barrier for transmission of HIV is a low 
frequency of activated target cells in the genital mucosa. Only ~20% of total human CD4+ 
T-cells are activated [21]. In Rhesus macaques, the majority of the CD4+ T-cells in the 
vaginal and ecto- and endo-cervial regions are of a resting phenotype. There are reportedly 
70 times more resting CD4+ T-cells than activated CD4+ T-cells in this compartment [22]. 
While these resting target cells can become infected, they tend to be self-limiting and 
produce small foci of founder viral populations in SIV models. Therefore, the low 
frequency of activated CD4+ target cells in the genital tract contributes to the inefficiency 
of HIV transmission.  
In addition to CD4+ T-cells, there is also an abundance of CD4+CCR5+ 
macrophages and dendritic cells in the genital mucosa. These cells are believed to play a 
major role in the early events of a productive HIV infection. Dendritic cells and Langerhan 
cells are capable of capturing virions and/or becoming infected [23-25]. DC-SIGN, a C-
type lectin receptor expressed on dendritic cells, is capable of binding HIV virions. DC-
SIGN captured virions can then be passed to target CD4+ T-cells [26]. These cells may also 
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play a role in trafficking of virions from the genital compartment to the gut mucosa [27], 
although the significance of these findings in the context of HIV transmission is not entirely 
clear. 
Another subset of cells that is believed to play a major role in the early events of 
transmission are Th17 cells. During acute HIV and SIV infection, there appears to be a 
preferential depletion of Th17 cells of the GALT, suggesting they are targets of robust viral 
replication [28-30]. The frequency of Th17 cells in the gut was shown to negatively 
correlate with plasma HIV or SIV load [31]. A loss of Th17 cells also correlated with SIV 
disease progression [32]. Additionally, a majority of Th17 cells express high levels of 
integrin α4β7, a lymphocyte gut homing receptor [33] described in great detail throughout 
this thesis.   
 
1.3 The HIV-1 Envelope Protein  
 
HIV is an enveloped retrovirus with a positive-sense single-stranded RNA genome. 
The HIV genome contains nine overlapping genes translated in multiple reading frames 
that are alternatively spliced to generate 15 proteins. The genome inside an HIV particle is 
protected by a viral capsid shell, which in turn is surrounded by the viral envelope (Figure 
1.4). The viral envelope is composed of the lipid membrane of the host cell of which the 
virion budded. This lipid membrane is studded with spikes of HIV envelope glycoprotein 
(Env), as well as host cellular receptors that were transiently or actively incorporated into 
the budding virion. Env on virions interacts with host receptor CD4 and coreceptors CCR5 
and CXCR4 to gain entry into target cells. In this way, Env is critical for viral entry and 
infection.  
 12 
The HIV Env protein is encoded by a roughly 2,550 base pair env gene that when 
synthesized into amino acid, encodes three distinct proteins. The Env propeptide is ~850 
amino acids (aa) long. The first segment encodes the signal peptide (SP) of the HIV Env 
protein which is ~30 aa in length. Much discussion of the SP is conducted below and is a 
major topic of research throughout this thesis. The SP is post-translationally cleaved 
resulting in a ~820 aa precursor protein known as gp160. The gp160 precursor protein is 
further processed into two functional proteins gp120 (~480 aa) and gp41 (~340 aa). The 
gp120 and gp41 proteins non-covalently bind to form heterodimers. These dimers in turn 
form trimers known as Env trimer spikes. The spikes are transported to the surface of 
infected cells, and are incorporated into budding virions with the help of the viral protein 
Gag.  
 
Figure 1.4. The HIV envelope proteins gp120 and gp41 coat HIV particles. (A) 
Schematic of an HIV particle coated with Env spikes. (B) The Env proteins gp120 and 
g41 associate non-covalently to form heterodimers. These dimers form trimers that 
make up the Env spike. (C) The HIV env gene encodes a signal peptide, gp120 and 
gp41. This is translated as one propeptide which is processed into mature Env proteins.   
 
Each of the two functional Env proteins is further characterized into functional or 
structural domains. The gp120 protein is divided into sequentially numbered conserved 
(denoted as C) and variable (denoted as V) domains: C1, V1, V2, C2, V3, C3, V4, C4, V5, 
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C5. These domains or loops of gp120 are created during the post-translational processing 
of Env that is discussed in detail in the next section and a topic of research included in this 
thesis. The gp41 protein is divided into the fusion peptide domain (FP), the helical N-
terminal heptad repeat (NHR), the C-terminal heptad repeat (CHR) and the trans-
membrane domain (TM).  
Viral entry into a host cell is accomplished by interactions between the Env spike 
and host cellular receptors. The main target cells of HIV are CD4+ T-cells and CD4 is the 
primary receptor for HIV. A hallmark of HIV disease is a substantial depletion of CD4+ T-
cells in the peripheral blood as well as in the gut associated lymphoid tissues (GALT) as a 
result of the infection and destruction of these cells. The loss of these critical CD4+ immune 
cells is also attributed to the compromised immune system that characterizes the 
progression of HIV disease into AIDS.   
The Env spike on HIV targets CD4+ T-cells for infection by binding directly to 
CD4 through a discontinuous epitope on gp120. CD4 binding to gp120 causes a 
conformational shift in Env revealing an otherwise inaccessible co-receptor binding site on 
gp120. This conformational shift allows for efficient co-receptor binding to the co-receptor 
binding site. There are two major co-receptors for HIV entry, CCR5 and CXCR4. Upon 
co-receptor binding to Env, gp41 undergoes extensive rearrangement revealing the FP 
domain of gp41, and brings the viral membrane in close proximity to the target cell 
membrane. The FP domain of gp41 is then inserted into the membrane of the target cell 
allowing for fusion of the two membranes to occur.  
Due to the expression of Env on virion surfaces and the role of Env in viral entry, 
much work has been done in the characterization of Env epitopes with the aim of targeting 
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key Env regions for preventative and therapeutic strategies. In this regard, many 
monoclonal antibodies (mAbs) have been isolated from immunized and HIV/SIV/SHIV 
infected animals, as well as HIV infected and immunized humans. These mAbs target 
several epitopes of Env with varying degrees of neutralizing capacity. Major sites of 
neutralizing antibodies are: the V1/V2 loop, the CD4 binding site, the V3 glycan patch, the 
gp120/gp41 interface and the membrane-proximal external region (MPER) located in the 
gp41 ectodomain adjacent to the viral membrane.  
Crystal structures of various Env-specific mAbs with recombinant Env proteins and 
peptides have been solved. This structural data provides a snapshot of the structures and 
conformations in which Env can adopt and present. These crystal structures have 
determined that Env is exceptionally fluid in its structure in that several domains of gp120 
can adopt multiple distinct conformations. This is particularly true for the V1V2 loop of 
gp120, which is a major topic of this thesis.   
As mentioned previously, the only HIV vaccine trial to elicit any protective immune 
response was the RV144 Thailand HIV vaccine trial. This trial provided only moderate 
protection from HIV infection. The vaccine consisted of a DNA prime, protein boost 
regimen via four doses over 24 weeks. The prime, ALVAC-HIV (vCP1521), consisted of 
an inert form of canary pox virus vector. This vector is derived from an avian virus and 
does not cause disease or replicate in humans. It has previously been used in cancer vaccine 
candidates. The canary pox vectored prime contained genetically engineered versions of 
the gag, pol and env genes of HIV. The Env included in this vector expresses the 92TH023 
isolate gp120 (subtype E) linked to the LAI isolate gp41 (subtype B). HIV subtype A/E, 
where the Env sequence is from the ancestral E subtype, is the predominant circulating 
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subtype in Thailand. The prime was given at weeks 0 and 4, and was intended to induce 
cellular immunity to HIV. At weeks 12 and 24, the ALVAC prime was given in addition 
to an AIDSVAX B/E boost. The AIDSVAX boost consisted of recombinant gp120 proteins 
from subtype E (CM244; A244) and subtype B (MN). This protein boost was intended to 
induce a neutralizing antibody response to Env. The trial enrolled over 16,000 volunteers, 
half of which received the complete vaccine regimen, while the other half was administered 
a placebo. The recipients were followed for three years for vaccine safety and efficacy as 
well as immune response analysis. 
The observed vaccine efficacy for RV144 was 31.2% [14]. The surprising finding of 
moderate vaccine efficacy initiated a global interest in identifying potential mechanisms of 
protection and immune correlates of reduced risk of acquisition. Analysis of samples 
obtained 2 weeks after the final immunization of 205 uninfected vaccinees and 41 
vaccinees who became infected identified the binding of IgG Abs to the V1V2 region of 
Env correlated inversely with the rate of infection [34]. Researchers also found that 
neutralizing antibodies did not correlate with the risk of infection. In fact, while RV144 
was able to induce long lasting memory responses in a subset of vaccine recipients, the 
vaccine regimen did not induce bNabs [35]. Further sequence analysis of breakthrough 
viruses identified positions 169 and 181 in the V2 region of Env as the targets of vaccine 
induced immune pressure [36]. This finding suggests that vaccine-induced V2 responses 
played a role in the partial protection conferred by the RV144 vaccine regimen. The 
significance of these two residues in the V2, the way in which they are presented 
structurally, and their potential role in HIV disease is a major topic of this thesis. 
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1.4 HIV-1 Env Post-translational Processing 
 
The Env proteins gp120 and gp41 are translated as a single gp160 propeptide from 
the env gene in the HIV genome as introduced in the preceding section. Much like all other 
secreted or transmembrane proteins, the Env propeptide contains a signal peptide (SP) 
(Figure 1.4). The SP of Env is unusually long (30aa) and is post-translationally cleaved 
from gp160. The gp160 protomer is further processed by cleavage into separate gp120 and 
gp41 proteins. These proteins non-covalently form dimers. The gp120/gp41 dimers in turn 
form trimers that decorate mature virions. However, much is done in the way of post-
translational processing before the Env proteins are incorporated into mature virions.  
Translation of the Env transcript into an amino acid chain is initiated by a ribosome 
in the cellular cytosol (Figure 1.5). The first amino acids of Env to emerge from the exit 
tunnel of the translating ribosome contains the SP. Once the SP has emerged, it is bound 
by a ribonucleoprotein complex known as the Signal Recognition Particle (SRP). Binding 
of the SRP to the SP causes a pause in protein synthesis known as elongation arrest, giving 
time for the SRP-SP-ribosome-mRNA complex to traffic to the Endoplasmic Reticulum 
(ER) membrane. This trafficking is achieved by SRP binding to its ER-membrane-
embedded SRP receptor (SRPr). Once docked on the SRPr, the ribosome-mRNA-SP 
complex is transferred to the ER channel protein called the translocon complex, and the 
SRP-SRPr complex dissociates. The SP is inserted into the pore of the translocon, and 
hydrophobic residues in the SP mediate its incorporation into the membrane of the ER. 
Because the SRP is dissociated from the translation complex, translation of the Env protein 
continues. As the remaining Env mRNA transcript is translated, the newly synthesized 
amino acid chain traverses the pore of the translocon by Brownian ratchet, and the nascent 
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peptide emerges inside the lumen of the ER. The gp41 transmembrane (TM) domain 
contains a membrane anchor known as a stop-transfer signal. This signal is embedded into 
the ER membrane preventing gp160 from being fully released into the ER lumen and 
presenting Env in the correct orientation for expression on the surface of the cell. The SP 
is then post-translationally cleaved by an ER resident signal peptidase and the gp160 
continues on the maturation pathway.  
 
Figure 1.5. The role of the signal peptide in early- and post-translational 
processing. The SP of HIV Env is the first domain of the Env polypeptide to be 
translated and exits the translating ribosome first. Attachment of the newly synthesized 
SP by a signal recognition particle (SRP) targets the peptide-translating ribosome to 
the translocon pore of the ER. Once at the translocon of the ER, translation of the 
remaining polypeptide continues into the ER lumen. The SP of gp120 is cleaved post-
translationally as initial post-translational modifications are made. 
 
Even before the SP is cleaved from gp160, glycans are added to the nascent 
propeptide. As with all N-linked glycosylation, the initial glycan structure, 
Glc3Man9(GlcNAc)2, is added to the asparagine of N-linked glycosylation motifs (NxS/T, 
where x is any amino acid except proline). This takes place in the ER by a resident 
glycosyltransferase. The terminal Glc3Man9 glycan structure is extensively modified by 
ER glycosidases and glycosyltransferases, which sequentially remove terminal mannose 
(Man) residues and add other glycans (Figure 1.6).  
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HIV Env is one of the most glycosylated proteins known to man. In fact, half of the 
molecular weight of the HIV glycoprotein is contributed by glycans. One hypothesis for 
the excessive glycosylation of Env is to shield critical epitopes on the protein from 
neutralizing antibodies. HIV gp120 has on average 25 N-linked glycosylation sites but this 
number ranges widely from 18 to 33 (Figure 1.6). Many of these N-linked glycosylation 
sites are located in the variable loops of gp120, while some are located in the core of gp120 
and to a lesser extent in gp41.  
  
 
Figure 1.6. Glycosylation of the HIV Envelope protein. (A) Histogram of the 
number of potential N-linked glycosylation sites (PNGSs) of 6635 gp120 sequences 
from the Los Alamos HIV Sequence Database. (B) N-linked glycans are added as high 
mannose structures in the ER which are subsequently trimmed and modified into more 
complex carbohydrate glycans as the glycoprotein traverses the ER-Golgi network.    
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While still in the ER, and with the assistance of resident chaperone proteins like 
calnexin (whose interaction with gp160 is modulated by the Env SP), immature gp160 
begins to fold into its native structure. The importance, and complexity, of N-linked 
glycosylation in Env folding, structure and function has been extensively studied. The 
glycosylation inhibitor, tunicamycin, disrupts the cleavage of the SP from gp160 due to 
aberrant folding which leads to retention in the ER. Disruption of N-linked glycosylation 
motifs by direct mutation have shown that key glycosylation sites are necessary for the 
correct folding of gp120. In addition, glycosylation inhibitors reduce the secretion of 
recombinant gp120 into cellular supernatants while retaining immature gp120 in cell 
lysates. Cells transfected with Env expression constructs do not produce gp120 capable of 
binding CD4 in the presence of several such glycosylation inhibitors. These data show that 
glycosylation is necessary for the correct folding of gp120.  
After initial folding is complete in the ER, oligomerization of gp160 begins and 
Env trimer spikes are formed. Studies have shown that mutating asparagine residues in the 
core of gp120 to structurally similar glutamines or alanines, results in misfolding and a 
reduction in trimer formation. This suggests that at least some glycosylation is required for 
the correct folding and trimerization of gp160.  
In the Golgi, gp160 is proteolytically cleaved by the cellular protease, furin [37] at 
a highly conserved K/R-X-K/R-R motif [38, 39]. Non-covalent interactions maintain the 
association of gp120 and gp41. However, Env is rapidly recycled from the surface of the 
cell by endocytosis [40, 41] and some gp120 is shed. The internalization and shedding of 
gp120 result in low levels of Env incorporation into virions (~10 Env spikes/virion) [42]. 
While Env trimer spikes are incorporated into virions and involved in viral entry, 
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incompletely-processed or non-trimer associated Env are also incorporated. The relative 
abundance of this immature Env in the context of virions is not well understood, nor is its 
role.  
 
1.5 The Connections Between HIV and 47  
 
Our laboratory has extensively reported on an intriguing interaction between the 
HIV Env protein gp120 and the integrin α4β7 (α4β7) on lymphocytes [43-45]. Env gp120 
not only binds to α4β7, but it also provides a signal to the cell through α4β7 leading to 
activation and the expression of LFA-1. This interaction appears to have evolved in 
mimicry of the interaction between α4β7 and its natural ligand, mucosal vascular addressin 
cell adhesion molecule 1 (MAdCAM). Integrin α4β7 is expressed on T-, B-, and NK- cells. 
MAdCAM is constitutively expressed on the high endothelia venules (HEV) in Peyer’s 
patches (PP) that line the gut. The binding of α4β7 to MAdCAM is a critical step in the 
lymphocyte multistage adherence cascade: tether, roll, activate, adhere, and then 
extravasate through the endothelia layer to the tissue compartment (Figure 1.7). Because 
of the gut-tropic expression of MAdCAM and the nature of its interaction with α4β7, the 
integrin is known as the gut-homing receptor. The finding that HIV has adapted the ability 
to interact with the gut-homing receptor, integrin α4β7, paired with the gut-tropic nature of 
transmission and acute infection of HIV, makes for an implicit connection and compelling 
story.  
In healthy humans, α4β7 plays two biological roles 1) aiding in lymphocyte cell 
migration and tissue homing and 2) providing a secondary, costimulatory signal to T-cells. 
Regarding the first function, α4β7 maintains the unique capacity to mediate lymphocyte 
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homing to the GALT, a major site of HIV replication. This process of migrating and 
homing to the gut is highly ordered. Migrating lymphocytes face extreme conditions in the 
shear force and high pressure that is present in the microvenules in which they travel. 
Therefore, overcoming this stress is a significant challenge. To mitigate these conditions, 
an array of adhesion molecules, including α4β7, on the surface of migrating cells as well as 
the cells lining the endothelial vessels participate in a multistep adhesion cascade. The first 
step of this cascade involves the tethering and rolling of lymphocytes to the endothelial 
layer lining the vessels. This is mediated by L-selectin on lymphocytes binding to sialyl-
Lewis structures that decorate the glycans of endothelia receptors involved in this stage. 
MAdCAM contains sialyl-Lewis structures involved in binding L-selectins during this 
step. This interaction mediates the rolling of the lymphocyte along the vessel wall. Integrin 
α4β7 in its intermediate state and its ligand MAdCAM are also involved in this tethering 
and rolling step [46, 47]. The initial rolling and tethering interaction to the endothelial 
vessels activates the second step in the cascade: signaling by chemokines. The release of 
chemokines induces the activation of α4β7 to the extended, open conformation. Other 
integrins including α4β1 and LFA-1 are also activated in this step. In the third phase, firm 
arrest of lymphocytes takes place through strong adhesive interactions between 
lymphocyte integrins and their ligands on endothelial cells. Extravasation through the 
endothelial layer into the tissue is the final step of this cascade. The α4β7 -MAdCAM 
interaction is involved in the rolling adhesion and firm arrest steps of the cascade. This is 
critical for α4β7+ T-cell homing to the lymph nodes and PP of the GALT.  
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Figure 1.7. The role of α4β7 in the lymphocyte multistep adhesion cascade. A 
schematic depicting lymphocyte tethering, rolling, activation and firm-arrest along the 
endothelial cells of a microvenule. The cascade begins with low affinity tethering of 
lymphocyte receptors to selectins on the endothelial cell. This tethering leads to rolling 
of the lymphocyte which involves α4β7 and MAdCAM. This is followed by subsequent 
activation of the lymphocyte. After activation of the lymphocyte, the active, extended 
conformation of α4β7 interacts with high affinity to MAdCAM on the endothelial 
membrane causing firm arrest. Integrin activation and increased affinity for MAdCAM 
and VCAM are critical for the cell arrest that precedes extravasation into the tissue.   
 
As alluded, integrin α4β7 can adopt at least three distinct conformations: bent 
(inactive), extended (intermediate), and open extended (active). The intermediate 
conformation of α4β7 is associated with low affinity binding to MAdCAM while the open 
conformation is associated with higher affinity binding to MAdCAM. The active state of 
α4β7 is regulated by intracellular signaling that modulates its conformation. During the 
multistage adhesion cascade, the extended/intermediate conformation mediates rolling 
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adhesion to MAdCAM while the open extended/active conformation mediates firm 
adhesion.  
Integrin α4β7 binds to an LDT tripeptide motif in its natural ligand, MAdCAM, in 
a divalent cation-dependent manner. The strength of the interaction between α4β7 and 
MAdCAM can be modulated by manipulating the cation concentration. The interaction is 
highest in the presence of Mn++ and weakest in the presence of Ca++. The interaction has 
intermediate strength in the presence of Mg++ and has no binding in the presence of EDTA, 
a metal cation-chelating agent. It is the coordination of a divalent cation in the metal ion 
dependent adhesion site (MIDAS) of β7 that bridges the aspartic acid of the MAdCAM 
LDT motif to α4β7. Because the MIDAS metal ion identity impacts the coordination 
geometry, using the different divalent cations mentioned above can modulate the affinity 
of the interaction.  
Integrin α4β7 binds to a highly conserved LDV/I motif at positions 179-181 in the 
V2 loop of gp120. This interaction is also divalent cation-dependent. The binding of gp120 
to α4β7 is inhibited by MAdCAM and small molecule mimetics of the LDV/T motif. 
Subsequent studies have identified a second, more cryptic, motif that is involved in the 
interaction between α4β7 and gp120 slightly upstream of the LDV that includes the residues 
QKE at position 170-172 [45].  
In vitro, CD4+ T-cells that express high levels of α4β7 are preferentially infected by 
HIV and later depleted [44], presumably due to the cell death associated with cellular 
infection. The CD4 receptor has been shown by immunofluorescence and FRET imaging 
to co-localize with α4β7 as well as CCR5, an entry co-receptor, on CD4+ T-cells activated 
with gp120. Unlike CD4 and CCR5, however, α4β7 is not an entry receptor nor is it required 
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for infection in vitro. That this CD4-CCR5-α4β7 complex is presented together on ideal 
target cells for HIV infection, suggests a role for α4β7 in HIV infection, although this role 
has yet to be determined.  
Studies using a non-human primate model of SIV transmission support a role for 
α4β7 in the establishment of SIV infection in the GALT [33, 48, 49]. In collaboration with 
Professor Aftab Ansari and others at Emory University, our group has antagonized the 
interaction between α4β7 and gp120 in nonhuman primate models of SIV transmission and 
acute infection. Pre-infusion of female rhesus macaques with an anti-α4β7 mAb challenged 
intravaginally with a weekly low-dose of pathogenic SIVmac251 lead to significant 
protection of half the treated animals, and a profound delay in infection of the animals that 
became infected [50]. Of note, the animals that received infusions of the anti-α4β7 mAb 
and became infected showed protection of CD4+ T-cells in the gut.  
An additional study was conducted to look at the impact of antagonizing α4β7 in the 
context of acute SIV infection. Rhesus macaques were infected with a high dose of 
pathogenic SIVmac239 and then placed on daily ART. After 4 weeks of ART, the animals 
were put on the same anti-α4β7 mAb infusions used in the study above. At week 18, ART 
was discontinued while Ab infusions continued. As expected, after termination of ART, 
the control animals had significant viral rebound. However, all 8 of the α4β7 treated group 
experienced either significantly lower viral rebound or no rebound at all. All 8 animals 
went on to control viremia to below detectable levels without any therapy [51]. During the 
phase of this study where the animals were undergoing dual therapy (simultaneous ART 
and α4β7 Ab administration), there was a rebound of the CD4+ T-cell population of the gut 
in the α4β7 mAb treated animals. The control animals never recovered their gut CD4+ T-
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cell population. Additionally, while all animals in the study had similar gp120-reactive 
sera, 8/8 of the α4β7 mAb treated animals but only 3/7 of control animals had sera that 
reacted against a cV2 peptide. This suggests that the α4β7 mAb treatment promoted a V2 
antibody response that is similar to the anti-V2 response observed in the RV144 vaccine 
trial.   
α4β7+/CCR5+/CD4+ memory T-cells are found in the rectal and vaginal mucosa 
where initial infection of cells is likely to occur during mucosal transmission [21, 44]. 
Several studies have shown that α4β7 mediates the trafficking of these potential target cells 
from the genital tract to mesenteric lymphnodes (MLNs) [52-54]. CD4+ T-cells are 
believed to be among the very first cells infected early in mucosal transmission [22, 26], 
however, it is not known whether they are also α4β7+. 
In humans, α4β7 expression on CD4+ T-cells is associated with cellular activation 
in that α4β7highCD4+ T-cells also express the T-cell activation markers CCR5, CD69, and 
Ki-67 [21, 44]. Because of HIV’s inefficiency in transmission, infecting activated cells 
likely represents a key step in establishing a productive infection. This likely contributes 
to the finding that HIV preferentially infects α4β7+/CD4+ T-cells in vitro. This also 
promotes the hypothesis that HIV evolved a specific affinity for α4β7 as a means of 
targeting ideally activated, highly susceptible cells with gut-homing potential. In this way, 
HIV would increase the likelihood of trafficking to the gut where a high proportion of 
target CD4+CCR5+ T-cells are located.  
On isolated human CD4+ T-cells, roughly half of the cells express medium levels 
of α4β7, while the other half expressed low levels of α4β7. In the MLN and PP, specialized 
DCs convert vitamin A into retinoic acid (RA). RA acts directly on T-cells to induce a gut-
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homing phenotype that includes increased α4β7 expression [43]. This gut homing 
phenotype can be recapitulated in vitro by culturing peripheral blood mononuclear cells 
(PBMCs) in the presence of RA. We have shown that PBMCs cultured in RA have higher 
levels of α4β7 and that these cells bind gp120 with greater efficiency that non-RA treated 
PBMCs.  
Our group has also shown that gp120 binding to α4β7 can induce intracellular 
signaling that leads to cellular activation. We originally showed that gp120 can activate the 
expression of LFA-1 [43]. While HIV virions are sufficient for infection, HIV can spread 
more efficiently through cell-to-cell transfer of HIV. This is accomplished through the 
formation and stabilization of a virological synapse (VS). Similar to an immunological 
synapse, a VS is a tight adhesive junction formed between an infected cell and an 
uninfected target cell, across which virus can be transferred efficiently. LFA-1 has been 
shown to play a role in the stabilization of the VS. As mentioned above, gp120 can activate 
LFA-1 expression suggesting a role for α4β7 in facilitating cell-to-cell spread of HIV. The 
additional observation that α4β7 colocalizes in clusters with CD4 and CCR5 on the surface 
of gp120 stimulated cells, further supports the hypothesis that α4β7 plays a role in HIV 
infection and cell-to-cell spread.   
 
1.6 Thesis Objectives 
 
1.6.1 Overview  
 Each section detailed above describes a distinct subject that has received incredible 
attention in the global efforts to prevent HIV transmission and treat HIV disease 
progression. We believe that all of these subjects – mucosal transmission of HIV, the post-
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translational processing of HIV Env and the interaction of gp120 with α4β7 – are connected 
in a fundamental way. Genetic signatures of HIV transmission modulate gp120 post-
translational processing which significantly impacts the structure of gp120 in a way that 
influences its interaction with its receptors including α4β7. Studying such genetic signatures 
will shed light on events surrounding transmission and acute HIV infection. It is our hope 
that the information presented as part of this thesis supplements the understanding of HIV 
transmission, and contributes in a serious way to the field’s efforts of developing a robustly 
protective HIV vaccine.  
 
1.6.2 Objectives 
 To further our understanding of the impact of protein processing on HIV Env 
structure and function in the context of HIV transmission, I have advanced several research 
projects to address shortcomings in these areas individually and make connections between 
them.  
In chapter 2, I present work examining the role of the HIV Env SP in influencing 
key characteristics of gp120 structure and function. We show that the SP alone can 
influence the glycosylation pattern of recombinant gp120 proteins in a significant way that 
alters its interaction with transmission-relevant host receptors. We also show that the 
altered glycosylation profile observed for these recombinant proteins mediated by the SP 
have major influence on the antigenicity of the gp120s. I go on to show that, in the context 
of infectious molecular clones, the SP can impact the neutralization sensitivity of virions 
to anti-V2 domain neutralizing antibodies. These studies make the connection between 
genetic signatures of transmission and potential structural or functional targets that, due to 
selective pressure, provide some isolates with increased transmission fitness.    
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In chapter 3, I describe the epitope of an interesting class of weakly neutralizing 
anti-gp120 V2 domain mAbs that inhibit the adhesion of α4β7 and gp120. These antibodies 
recognize a helix/coiled conformation of the V2 loop that I show is present on incompletely 
processed Env and is also present on mature virions. Some of these mAbs were isolated 
RV144 vaccine recipients. That this epitope, which is precluded from the stabilized Env 
trimer and is associated with ER-Env, interacts with α4β7 in an overlapping epitope with 
the RV144 sieve sites brings the intriguing possibility that the weakly neutralizing Ab 
response of RV144 may be connected to this interaction.   
In chapter 4, I describe the links between the influence of genetic signatures of 
transmission on glycosylation of gp120 discussed in chapter 2 and the role of glycosylation 
and structure of the V2 interaction with α4β7 in chapter 3. I discuss their connections in the 
context of HIV transmission and early infection. Also discussed are the questions that still 
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THE HIV ENV SIGNAL PEPTIDE IMPACTS VIRAL NEUTRALIZATION 




2.1 Abstract   
 
The HIV-1 Envelope protein (Env) of early-replicating viruses encode several 
distinct transmission signatures. One such signature involves a reduced number of potential 
N-linked glycosylation sites. This transmission signature underscores the importance of 
post-translational modifications in the fitness of early-replicating isolates. An additional 
signature in Env involves the over-representation of basic amino acid residues at a specific 
position in the Env signal peptide (SP). We investigated the potential impact of this SP 
signature on gp120 glycosylation, antigenicity and viral neutralization. To this end, two 
recombinant gp120s were constructed, one derived from an isolate that lacks this signature 
and a second from an early-replicating isolate that includes this signature. Chimeric gp120s 
were also constructed in which the two SPs were swapped between the isolates. All four 
gp120s were probed with glycan-, structure- and receptor- specific probes in a surface 
plasmon resonance binding assay. We found that the SP of Env influences qualitative 
aspects of Env glycosylation that in turn affect the antigenicity of Env in a major way. The 
SP impacts the affinity of Env for DC-SIGN, a lectin receptor expressed on dendritic cells 
that is believed to play a role in mucosal transmission. Additionally, affinity for the 
monoclonal antibodies 17b and A32, which recognize a CD4-induced, open conformation 
of Env is also altered. To investigate the impact of SP variation in the context of whole 
virus, we generated chimeric infectious molecular clones (IMCs) whereby the Env SP of 
the viral backbone was individually swapped with 11 alternate SPs from diverse isolates. 
We found that the SP of these IMCs significantly impacted neutralization by anti-gp120 
V2 domain mAbs. These results demonstrate that natural variation in the SP of HIV Env 
can significantly impact the antigenicity of mature gp120 and influence characteristics of 
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viral neutralization. Thus, the SP is likely subject to antibody-mediated immune pressure 






Transmission of HIV across mucosal tissues involves a complex, yet strikingly 
inefficient, series of events that are not fully understood [1, 2]. It has been shown that 
among the quasi-species of virus replicating in an infected, sexually transmitting person, 
very often, only a single isolate establishes infection in the recipient partner [3, 4]. Studies 
suggest that this genetic bottleneck is not stochastic [3, 4]. Rather, specific structural 
features of the Env appear to provide transmitting isolates with increased transmission-
fitness [5, 6]. The transmitting virus diversifies over time in infected subjects [7] due to 
random mutations introduced by error prone replication, which are then subjected to 
immune selective pressure.  
The HIV Env is extensively glycosylated, with up to 50% of the mass of gp120 
comprised of glycans [8]. However, the number of potential N-linked glycosylation sites 
(PNGSs) varies significantly between isolates, with a range of 18 to 33 and a median of 25 
[9, 10]. Genetic signatures in transmitting HIV isolates have been linked to Env [11, 12]. 
The best-characterized signature involves a reduced number of PNGSs in transmitting 
isolates [12]. In addition, shorter variable loops in gp120 have been correlated with this 
decrease in PNGSs [13]. Mass spectrometry analysis of the glycan profiles of Env from 
transmitting viral isolates in acute infection shows increased high-mannose residues 
compared to the glycan profile of Env from chronic phase isolates further suggesting a link 
between Env glycan content and transmission [14]. It is currently unknown by what precise 
mechanisms these alterations in glycosylation influence transmission-fitness. One 
possibility is that altered glycosylation can directly influence the interaction of Env with 
host cell surface receptors [15], which in turn increase infectivity. Another widely accepted 
 37 
hypothesis is that once infection is established, the appearance of new PNGSs may shield 
critical epitopes from neutralizing antibodies that evolve during the course of infection.  
A second genetic signature, identified in subtype B isolates, involves an over-
representation of basic amino acids, particularly histidine, at position 12 of the Env signal 
peptide (SP) of transmitting viral isolates (Figure 2.1), which is lost in chronic phase viral 
isolates [11, 16]. The presence of a signature in this region of the Env SP of transmitting 
viral isolates has also been confirmed in SIV and SHIV transmission studies [17]. The SP, 
which lies at the N-terminus of the amino acid sequence of proteins destined for transport 
to the cell surface or for secretion, directs these nascent peptides to the endoplasmic 
reticulum (ER) where translation continues, coincident with protein processing (Figure 
1.5). In the ER, disulfide bonds form and undergo isomerization [18]. Of note, the addition 
of high-mannose glycans begins in the ER (Figure 2.1). The SP is then cleaved before 
transport of the maturing peptide from the ER to the Golgi where further folding and post-
translational processing, e.g. tyrosine sulfation and complex glycan modification, occur 
[19]. These post-translational modifications (PTMs), particularly glycosylation, have been 
shown to greatly influence the structuring of mature proteins as well as protein function 
[20-22]. 
HIV Env SPs show a high degree of sequence diversity (Figure 2.1); however, 
several conserved structural features have been identified. Much like the SP of all secreted 
or membrane proteins, the Env SP includes a positively charged n-region, a hydrophobic 
core (h-region) and a cleavage domain. These regions strongly influence the rate of 
processing of Env as it transits through the ER and Golgi [23-26]. This is believed to alter 
Env synthesis including the trafficking of nascent Env to the ER, the rate of SP cleavage 
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inside the ER and/or the retention time of Env in the ER. Asmal et al concluded that the SP 
signature at position 12 provides transmitting HIV isolates with higher overall Env 
expression, which translates into higher Env incorporation into virions [11].  
 
Figure 2.1. HIV Env SP role in early HIV Env processing and glycosylation. (A) 
N-linked glycans are added in the ER to the asparagine in an N-linked glycosylation 
sequon of nascent peptides as Glc3Man9GlcNAc2. The three Glcs are sequentially 
removed followed by removal of one Man residue. This glycosidase activity is 
intimately associated with glycoprotein folding assisted by ER resident chaperones and 
determines whether a protein traffics to the Golgi or is degraded by the proteasome. 
Once in the Golgi, the glycans are further modified with the addition of GlcNAc, Gal, 
Fuc, sialic acids, or other complex saccharide linkages. Gal, galactose; Glc, glucose; 
GlcNAc, N-acetyl glucosamine; Fuc, fucose; Man, mannose. (B) Sequence logo of 
natural variation found in 2,025 Clade B HIV Env SP sequences from the Los Alamos 
National Laboratory HIV Database using Weblogo 3. The height of each symbol 
indicates relative frequency of each amino acid at that position. Amino acid symbols 
are color coded for hydrophobicity: blue, hydrophilic; green, neutral; black, 
hydrophobic. (C) SP amino acid sequence alignment of the SP of the early-replicating 
isolate bearing the SP transmission signature and of the isolate that does not bear the 
SP transmission signature. Amino acid residues are color coded for side chain 




There are no studies to date that investigate how natural variation in the SP impacts 
the overall structure or antigenicity of Env or how SP variation impacts neutralization by 
monoclonal antibodies (mAbs). Identification of a transmission signature located in a 
region of the SP sequence that is absent in the mature full-length protein (Figure 2.1), 
suggests a potential role for SP variation in impacting Env structure and function. Thus, 
SP variation may be subject to immune pressure despite the fact that this domain is absent 
from the mature protein.  
Given that we now have evidence for SP selection in the context of HIV 
transmission, we sought to determine whether the natural variation that occurs in SPs 
impacts Env glycosylation and structure, which in turn could influence Env antigenicity 
and its ability to be neutralized by bnAbs. Here, we provide evidence that naturally 
occurring variation in SP can impact both Env glycosylation and structure in a way that 
might potentially impact the efficiency of replication in early-transmitting viruses. We also 
show that the SP can impact the neutralization profile of replication competent viruses. Our 
findings provide evidence that natural variation in the SP of Env can influence a key 
antigenic feature of gp120 in a major way. In addition, we demonstrate that antigenic 
manipulation of Env in the context of a vaccine can be carried out by simple modification 
of the SP. 
 
2.3 Experimental Procedures and Methods 
 
2.3.1 Recombinant gp120 Production and Purification 
Two HIV-1 clone sequences from HIV-1-positive patients deposited into the HIV 
Database at Los Alamos National Library were used in this study: an early-replicating 
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isolate bearing the SP transmission signature termed ‘early-replicating’ (Genbank 
accession #EU289198), and a non-SP transmission signature bearing isolate termed 
‘chronic’ (Genbank accession #EU575870). Both full-length gp120 DNA sequences were 
synthesized for expression in mammalian cells (ATUM). The constructs were designed 
such that swapping of the wildtype SP with an alternative SP could be achieved by single 
digest and insertion of the complimentary SP without alterations to the mature gp120 
protein sequence. Using this approach, two additional recombinant gp120 constructs were 
generated: early-replicating gp120 with chronic SP and chronic gp120 with early-
replicating SP. All recombinant gp120s were produced and purified in the same manner. 
Vectors were transiently transfected into CHO-S-Freestyle cells (Invitrogen) using 
FreeStyle MAX Reagent and Polyfect (Qiagen). Clonal cell lines were established and 
subsequently seeded into hollow-fiber cartridges (30 kD MW cutoff) (Fibercell Systems). 
Protein containing supernatants were harvested daily from the extra-capillary space. 
Pooled supernatants were then passed over a Galanthus nivalis lectin column (Vector Labs) 
and eluted with 500mM α-methyl-manno pyranoside (Sigma), desalted and passed through 
a cobalt-chelating column to remove contaminants. Protein was then passed over a 
superdex-200 26/60 gel-filtration column (GE Healthcare Bio-Sciences). Peak fractions 
were collected and concentrated with a stirred cell concentrator (Millipore) and dialyzed 
exhaustively against HEPES, pH 7.4, 150 mM NaCl. Proteins were quantified by UV 
adsorption at O.D λ280 with an extinction coefficient of 1.1 and the values were confirmed 
by a bicinchoninic acid protein assay (Pierce).  
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2.3.2 Surface Plasmon Resonance Analysis 
Surface plasmon resonance analysis was performed on a Biacore 3000 instrument 
(GE Life Sciences) using CM5 sensor chips. The data were evaluated with BIAevaluation 
4.1 software (GE Life Sciences). The chip surface was activated by injecting 35 μl of a 1/1 
mixture of 0.05 M N-hydroxysuccinimide and 0.2 M N-ethyl-N-
(dimethylaminopropyl)carbodiimide at 5 μl/min. Each of the four gp120s (5 μg/ml in 10 
mM NaOAc (pH 5)) were immobilized to a flow cell to a density of approximately 750 
resonance units (RU) and blocked with 35 μl of 1 M Tris-HCl (pH 8.0). For a background 
control, human IgG was immobilized to one flow cell.  HBS (pH 7.4), 0.005% Tween p20 
was used as running buffer. To evaluate gp120 characteristics Narcissus pseudonarcissus 
(Daffodil) lectin (200 mM), Ricin Comunis I (Castor Bean) lectin (200 mM), mAb 2G12 
(100 nM), soluble tetrameric DC-SIGN (200 mM) mAb 17b (100 mM), and mAb A32 (100 
mM) were individually injected over the surface-bound gp120s at a flow rate of 25 μl/min 
for 300 seconds. After probe injection, the surface was washed for 2 min with running 
buffer to follow the dissociation from the gp120s. The surfaces were regenerated by 
injection of 4.5 M MgCl2 at a flow rate of 50 μl/min. 
 
2.3.3 Infectious Molecular Clone Production 
 
 The NL4.3 viral backbone construct that has been described previously [27] was 
used to generate infectious molecular clones (IMCs). We took advantage of the backbone’s 
multiple restriction sites to insert an Env fragment containing the SP (Env position 1-30), 
the gp120 (position 31-509) and much of the gp41 (position 510-750 out of 854) from 
isolate SF162 (Accession #EU123924). We also inserted an Nhe1 restriction site into the 
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CSA SP cleavage motif. Therefore, by simple digest using the endogenous Sac1 restriction 
site just upstream of the SP and the inserted Nhe1 site in the new NL4.3-SF162env 
construct (+30), swapping of the SF162 SP for other heterologous HIV Env SPs could be 
accomplished. A total of 11 isolate sequences were used to generate NL4.3-SF162 SP 
chimera constructs: (Figure 2.6). All Env and SP cloning fragments were commercially 
synthesized (ATUM). Sanger sequencing of the wildtype and SP chimera virus constructs 
was done to confirm cloning (Genewiz).  
 Viral constructs were transiently transfected into HEK293T using polyfect reagent 
following the manufacturer’s protocol (Qiagen). Supernatants were harvested at day 7 and 
analyzed for virus production by p24 ELISA (Perkin Elmer). HEK293T supernatants 
containing virus were then used to inoculate OKT3, IL-2 and retinoic acid activated PBMC 
cultures. All NL4.3-SF162 293T viral supernatants were passaged through the same PBMC 
donor’s cells to negate donor-to-donor differences. PBMC culture supernatants were 
harvested on day 7 and analyzed for virus production by p24 ELISA (Perkin Elmer). 
Aliquoted stocks were frozen at -80 ºC until use.  
 
2.3.4. Infectious Molecular Clone Neutralization Assay 
 
   Virus neutralization of IMCs by bnAbs was measured with TZM.bl target cells 
using a β-galactosidase-based assay [28, 29]. Serial dilutions of mAbs were added to virus 
in a 96-well plate in duplicate or triplicate and incubated for 24 h at 37 ºC. After incubation, 
TZM.bl cells were added along with DEAE-dextran and incubated for 48 h. Relative 
luminescence was measured, and percent neutralization was calculated by comparing 





2.4.1 The HIV Env signal peptide influences the molecular weight of gp120.  
To address the influence of the SP signature on Env characteristics associated with 
transmission, recombinant gp120 proteins were generated from viral sequences of HIV-
positive patients. We chose two gp120s from isolates previously evaluated in the initial 
Asmal et al report describing the SP signature associated with transmission [11]. First, a 
subtype B gp120 derived from a viral sequence isolated from an early-replicating isolate 
was generated. This gp120 contains a basic amino acid histidine at position 12 of the Env 
SP and is therefore referred to as “early-replicating” (Figure 2.2). A second recombinant 
gp120 was generated from an isolate from an infected patient that lacked this SP signature. 
This isolate was termed “chronic” since it did not bear the SP transmission signature 
(Figure 2.2). Two chimeric gp120s were then generated from these two constructs in which 
the SPs of the two isolates were swapped, resulting in the early-replicating gp120 with the 
chronic SP and a chronic gp120 with the early-replicating SP. Using the parental and 
chimeric gp120 sequences, we sought to determine if their SPs could influence important 
antigenic features of the gp120s.  
Size exclusion chromatography (SEC) provides an approximation of the Stokes 
radius of a protein. Although SEC does not provide a precise measure of molecular weight 
(M.W.), it can identify relative differences in the size of structurally related proteins. Using 
SEC, we asked whether the early-replicating and chronic gp120s encoding their wildtype 
SPs along with the two proteins encoding swapped SPs exhibited altered M.Ws. The 
calculated M.W. for the early-replicating gp120 was 102 kDa (Figure 2.2). Despite 
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containing the identical mature peptide sequence, the early-replicating gp120 with the 
chronic SP showed a M.W. of 179 kDa (Figure 2.2A). Thus, replacing the early-replicating 
SP with the chronic SP substantially increased the M.W. of gp120.   
Conversely, the chronic gp120 with the early-replicating SP showed a decrease in 
M.W. compared to the chronic gp120 with its wildtype chronic SP (147 kDa vs 123 kDa) 
(Figure 2.2B). These SEC data indicate that variations in the SP of Env can have a 
significant impact on the M.W. of mature gp120 peptides.  
 
Figure 2.2. HIV Env SP impacts recombinant gp120 molecular mass. Size 
exclusion chromatography (SEC) chromatograms of the recombinant (A) early-
replicating gp120 with its wild-type SP (blue), the chronic SP (green), (B) the chronic 
gp120 with its wild-type SP (green), and the early-replicating SP (blue) produced in 
CHO-S cells and purified via Galanthus nivalis lectin column. (C) Tabulated 
molecular mass and molecular mass changes for all four proteins.  
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2.4.2 The HIV Env signal peptide influences gp120 glycosylation.  
The SEC results described above suggested that variations in the SP of Env may 
influence the maturation process of gp120. Of the PTMs of the Env, glycosylation has been 
shown to account for a significant fraction of the M.W. of the protein [8]. Therefore, we 
sought to determine whether the changes in the gp120 M.W. that we observed were due, at 
least in part, to altered glycan processing. 
High-mannose carbohydrates are the initial glycans added to nascent peptides 
(Figure 2.1A) and are characteristic of immature glycoproteins. They are also associated 
with mature proteins that transit through the ER and Golgi in an accelerated way. 
Conversely, complex carbohydrates exhibit a higher M.W. than high-mannose glycans (2.4 
kDa vs 1.2 kDa) and are not formed until later in the processing pathway. With an average 
of 25 PNGSs on each gp120, changing all 25 from high-mannose occupied PNGSs to all 
complex glycan occupied PNGs would result in a ~30 kDa shift in M.W.  
To quantitate the relative amount of high-mannose glycans on the gp120s, we 
employed the Narcissus pseudonarcissus lectin, which is specific for α-linked mannose 
residues (Man), [30] in a surface plasmon resonance (SPR) assay. The early-replicating 
and chronic Env proteins, along with the two SP chimeras were immobilized to the surface 
of a biosensor chip. Narcissus pseudonarcissus lectin was passed over each of the four chip 
surfaces and the total accumulation of lectin bound to each surface was measured over 300 
seconds.  
This demonstrated significant Man content on the early-replicating gp120 with the 
wildtype SP (178.0 RU) (Figure 2.3A, Left). Man content was shown to be decreased when 
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we probed the early-replicating gp120 with the chronic SP (130.2 RU) (Figure 2.3A, Left). 
The inverse was found when looking at the two chronic gp120s; swapping the SP of the 
chronic gp120 to that of the early-replicating SP caused an increase in Man content (159.5 
RU vs 225.0 RU) (Figure 2.3A, Right). These results indicate that the SP alone can 
significantly influence the Man content of gp120. More specifically, the early-replicating 
SP, which may favor more rapid transit through the ER and Golgi compartments, increases 
the relative amount of high mannose carbohydrate present on the two gp120s we evaluated. 
We then probed each of the four gp120s with a lectin derived from Ricinus 
communis that preferentially binds complex oligosaccharides ending in galactose (Gal) 
[31]. The early-replicating gp120 showed little detectable reactivity to Ricinus communis 
lectin (17.8 RU) (Figure 2.3B, Left). In contrast, the same gp120 encoding the chronic SP 
reacted strongly (494.4 RU) to Ricinus communis lectin. Thus, the chronic SP substantially 
increased the amount of complex oligosaccharides ending in Gal in the early-replicating 
gp120.  
Consistent with this observation, the chronic gp120 encoding its wildtype SP also 
reacted strongly with Ricinus communis lectin (558.8 RU), while the same protein 
encoding the early-replicating SP showed little or no reactivity with Ricinus communis 
lectin (12.6 RU) (Figure 2.3B, Right).  
Taken together, these results indicate that the chronic SP promotes the addition of 
complex glycans bearing terminal Gal.  
Overall, the manner in which the two SPs differentially impacted the presentation 




Figure 2.3. HIV Env SP influences gp120 glycosylation profile. Four recombinant 
gp120s were evaluated for glycan composition in a surface plasmon resonance (SPR) 
assay probing with (A) N. pseudonarcissus lectin specific for α-linked mannose 
residues and (B) R. communis I lectin specific for oligosaccharides ending in galactose. 
(C) The four gp120 were also probed with the glycan-dependent mAb 2G12. (Left) 
Sensograms of the early-replicating gp120 with wild-type SP (blue) and with the 
chronic SP (green), and (Right) sensograms of the chronic gp120 with its wild-type SP 
(green) and with the early-replicating SP (blue). Peak response units (RU) are 
presented and circled above each curve.  
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appeared to favor the presentation of high-mannose on either the early-replicating or the 
chronic protein while the chronic SP favored at least one form of complex carbohydrate.  
HIV gp120 monoclonal antibodies (mAbs) specific in whole or in part to glycan 
patches on gp120 have been isolated from HIV infected individuals [32-34]. A number of 
these mAbs show broad and potent neutralizing activity [32, 34, 35]. 2G12 is the 
prototypical glycan-dependent mAb [33, 36]. It recognizes a discontinuous di-mannose 
epitope located in the C3 region and the base of the V3 loop in an area often referred to as 
the silent face of gp120 [36]. When probed with mAb 2G12, the early-replicating gp120 
encoding the chronic SP showed decreased reactivity compared to the same gp120 
encoding the early-replicating SP (72.5 RU vs 88.9 RU) (Figure 2.3C, Left). The chronic 
gp120 with the early-replicating SP showed increased binding to 2G12 compared to the 
chronic gp120 with its wildtype chronic SP (125.5 RU vs 84.9 RU) (Figure 2.3C, Right).  
Taken together, these results demonstrate that the reactivity of glycan specific 
antibodies to gp120 can be influenced by the SP. Regardless of mature gp120 sequence, 
the SP of the early-replicating Env biased the mature protein to a high Man, low complex 
carbohydrate profile. Conversely, the SP of the chronic gp120 biased the gp120 to an 
increased complex carbohydrate profile. Because Man is roughly half the molecular weight 
of an average complex glycan (~1.2 versus ~2.4 kD), and carbohydrate comprises about 
half the mass of a gp120 surface protein, these alterations in glycan processing are likely 
playing a major role in the M.W. shift observed for these peptides shown in Figure 2.2.   
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2.4.3 The HIV Env signal peptide influences gp120: DC-SIGN interaction.  
C-type lectin receptors are thought to facilitate mucosal transmission of HIV [37, 
38]. Among these receptors, DC-SIGN is perhaps the most extensively characterized [39-
41]. The carbohydrate-recognition domain of DC-SIGN reacts with high affinity to the 
high-mannose residues that decorate gp120 [42-44]. Considering the capacity of the SP to 
influence the glycan content of gp120, we sought to determine whether SP variation could 
also influence gp120 interactions with DC-SIGN.  
Using tetrameric recombinant soluble DC-SIGN as a probe, we determined that the 
early-replicating gp120 with its wildtype SP showed higher reactivity to DC-SIGN than 
the early-replicating gp120 encoding the chronic SP (208.2 RU vs 130.6 RU) (Figure 
2.4A). When the wildtype SP of the chronic gp120 was replaced with the early-replicating 
SP, DC-SIGN reactivity nearly doubled (184.5 RU vs 308.4 RU) (Figure 2.4B).  
 
Figure 2.4. HIV Env SP influences DC-SIGN reactivity to gp120. (A) The early- 
replicating gp120 with its wild-type SP (blue) and with the chronic SP (green), and (B) 
the chronic gp120 with its wild-type SP (green) and the chronic gp120 with the early-
replicating SP (blue) were evaluated for reactivity to soluble tetrameric DC-SIGN, C-
type lectin receptor expressed on dendritic cells, in an SPR assay. Peak response units 
(RU) are presented and circled above each curve.  
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These results are consistent with the results presented above indicating that the 
early SP increases the relative proportion of Man presented on gp120, and suggest that the 
sequence variation encoded in the SP can alter interactions with lectin receptors, which 
may be relevant in the context of mucosal transmission.  
 
2.4.4 The HIV Env signal peptide influences gp120 antigenicity.  
Altered glycosylation profiles of Env can greatly influence structural and antigenic 
features of gp120 [45]. A prominent feature of HIV gp120s involves the induction of buried 
epitopes following CD4 ligation (CD4i epitopes). Such changes are conserved in both HIV-
1 and HIV-2 and have a significant impact on antigenicity and susceptibility of viruses to 
neutralizing antibodies [46, 47]. To understand if the changes in gp120 described above 
can influence protein antigenicity, we measured reactivity with structure-specific gp120 
mAbs. mAbs 17b and A32 recognize CD4i epitopes [48-51].  
As a control for this measure, and to establish that our SPR–based assay was able 
to detect CD4i epitopes that are impacted by glycosylation, we employed a wildtype 
subtype A gp120, 92UG037, and the same gp120 with a PNGS disrupting mutation, 
N144Q. These proteins were probed with mAbs 17b and A32. In the absence of CD4, mAb 
17b reacted well to the wildtype 92UG037 gp120 (22.9 RU) (Figure 2.5A, Left). This 
reactivity was completely abrogated in the N144Q PNGS mutant gp120 (0.0 RU) (Figure 
2.5A, Left). The same trend was observed when probing these two gp120s with the mAb 
A32, in that the wildtype gp120 had significant mAb A32 reactivity while the N144Q 
PNGS mutant had greatly reduced mAb A32 reactivity (54.6 RU vs 10.7 RU) (Figure 2.5A,  
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Figure 2.5. HIV Env signal peptide influences gp120 structure and antigenicity. 
(A) Subtype A gp120 92UG037 (blue) and the PNG mutant 92UG037 N144Q (green) 
were probed for reactivity with the CD4i mAbs 17b (Left) and A32 (Right) in an SPR 
assay to determine the impact of glycosylation on gp120 antigenicity. (B) Early-
replicating gp120 with wild-type SP (blue) and early- replicating gp120 with the 
chronic SP (green) were probed with mAbs 17b (Left) and A32 (Right) in an SPR 
assay. (C) Chronic gp120 with chronic SP (green) and chronic gp120 with the early-
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replicating SP (blue) were also probed with the mAbs 17b (Left) and A32 (Right). 
Peak response units (RU) are presented and circled above each curve. 
 
Right). These data confirm that altered glycosylation influences the ability of gp120 to 
adopt the CD4i open conformation recognized by mAbs 17b and A32. 
We next determined whether sequence variation in Env SPs could influence the 
antigenicity of gp120. To test this hypothesis, we probed our four recombinant gp120s for 
reactivity with mAbs 17b and A32 in the absence of CD4.  The reactivity to mAb 17b was 
reduced by more than half when the SP of the early-replicating gp120 was swapped from 
its wildtype SP to that of the chronic SP (14.9 RU vs 5.4 RU) (Figure 2.5B, Left). 
Additionally, the same trend of reduced reactivity of the early-replicating gp120 with the 
chronic SP was observed when the two proteins were probed with mAb A32 (46.5 RU vs 
28.1 RU) (Figure 2.5B, Right).  
We then probed the chronic gp120 with its wildtype SP versus the early-replicating 
SP with mAbs 17b and A32. We observed low reactivity of mAb 17b with the chronic 
gp120 with its wildtype SP (11.0 RU) (Figure 2.5C, Left). However, reactivity to mAb 17b 
increased four-fold when the SP of the chronic gp120 was swapped to that of the early-
replicating SP (46.1 RU) (Figure 2.5C, Left). When the two chronic gp120s were probed 
with mAb A32, reactivity of the mAb to the chronic gp120 with the early-replicating SP 
was increased two-fold when compared to the chronic gp120 with its wildtype SP (55.2 
RU vs 113.0 RU) (Figure 2.5C, Right).  
Taken together, these results show that the SP of Env can influence the reactivity 
of CD4i mAbs to mature gp120s. These data suggest that the glycosylation differences 
induced by natural SP variation can greatly influence the antigenicity of gp120. 
 
 53 
2.4.5 The HIV Env signal peptide impacts viral neutralization  
 
The above experiments sought to characterize the impact of the HIV Env SP using 
recombinant peptides. No studies to date have investigated the impact of natural variation 
in the Env SP on replication competent infectious molecular clones (IMCs). To investigate 
the impact of SP variation on viral neutralization we generated infectious molecular clones 
using an NL4.3 isolate backbone construct that contains the entire HIV genome and 
produces replication competent IMCs when transfected into mammalian cell cultures. 
Modification of the viral backbone was done by simple cloning digest to replace the SP, 
the gp120 and most of the gp41 of the NL4.3 construct to that of the well characterized 
isolate SF162. The new NL4.3-SF162env construct was additionally modified to create 
chimera SP constructs in that the SP of the SF162 Env was swapped individually with 11 
diverse isolate SP sequences (Figure 2.6). The NL4.3-SF162env IMC with the SF162 SP 
is referred to as wildtype (WT), while the SP chimera IMCs are referred to by their SP 
isolate name (i.e. NL4.3-SF162env with the SP of 398.F1 isolate is referred to as 398.F1). 
The resulting constructs were transfected into 293T cells and were passaged once through 
activated PBMC culture.  
Because we hoped to compare the neutralization profiles of these viruses without 
differences in infectivity as a confounding factor, we first tested whether the SP impacted 
in vitro infectivity by using a TZM.bl β-galactosidase-based infectivity assay. We found 
that all 12 (wildtype and 11 chimera SP) viruses had similar infectivity profiles in this assay 
(Figure 2.7). This shows that the SP does not significantly impact the in vitro infectivity of 
TZM.bl target cells by these IMCs. However, we are unable to make conclusions about the 




Figure 2.6. Sequence information for Env signal peptide chimera IMCs. (A) 
Details for the isolates from which the signal peptide (SP) sequence were derived for 
the generation of SP chimera IMCs. “Stage at isolation” refers to the timing of isolate 
isolation based on estimated or documented date of infection: early (<6 mo after 
infection) or late (>6 mo after infection). (B) Amino acid sequence alignment of the 
SPs used in the generation of the SP chimera IMCs. Alignment was generated using 
MAFT alignment program via MegAlign Pro software (Lasergene).   
 
To investigate the impact of SP variation on virus neutralization profile we 
employed the same infectivity assay as described above with an added 24 h pre-incubation 
of anti-gp120 mAb with the IMCs. Because we show that the SP can impact the 
accessibility of neutralizing epitopes on gp120, we reasoned that the SP may influence the 
viral neutralization by mAbs targeting the V2 loop of gp120, which is a major target of 
broadly neutralizing antibodies (bnAbs). We therefore tested these SP chimera IMCs for 
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neutralization sensitivity to anti-V2 loop neutralizing mAbs. Many of the well-




Figure 2.7. Infectivity of Env signal peptide chimera IMCs. Viral infectivity was 
determined by serially diluted amounts of chimera NL4.3-SF162envSP virus 
incubated with TZM.bl target cells. Infectivity was measured 48h later by β-
galactosidase activity assay.  
 
The chimera IMCs were first tested for neutralization by CD4-Ig, a known strong 
inhibitor of isolate SF162 infectivity in this assay. All chimera IMCs were comparably 
neutralized by CD4-Ig with ≥50% neutralization at 0.02 ug/mL (Figure 2.8). This suggests 
that these SP chimera IMCs are not differentially impacted by CD4 binding in a detectable 
way. We also tested neutralization by the irrelevant anti-parvovirus B19 mAb 1418. 
Neutralization by mAb 1418 was similar between our panel of SP chimera IMCs. This 
control data shows the extremes in neutralization sensitivity and susceptibility for our panel 
of SP chimera IMCs.  
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To investigate the impact of SP variation on viral neutralization by anti-V2 mAbs, 
we tested the neutralization of these chimera IMCs by the anti-V2 mAbs 2158, 830A and 
697-D (Figure 2.8). The WT IMC was largely resistant to neutralization by the anti-V2 
mAb 2158, only reaching above 50% neutralization at the highest concentration tested (100 
μg/mL). Interestingly, some but not all of the SP chimera IMCs were susceptible to 
neutralization by mAb 2158 (Figure 2.8). The 398.F1 IMC, reached ~75% neutralization 
at 20 μg/mL and ~90% at 100 μg/mL. This suggests that natural sequence variation in the 
SP can alter the V2 domain of gp120 of an IMC in a way that makes the virus more 
susceptible to neutralization by the mAb 2158.   
While we found that some SP variants can increase the susceptibility to 
neutralization by the V2 bnAb 2158, this was not always the case. When we investigated 
the neutralization profile of these SP chimera IMCs by another anti-V2 mAb, 830A, we 
found that the neutralization profile was not significantly altered (Figure 2.8). For the SP 
chimera IMCs that we tested, we found that all were largely susceptible to neutralization 
by mAb 830A (i.e. ~50% at 4 μg/mL).  
We hypothesized that in our investigation of viral neutralization by anti-V2 mAbs 
it would be likely to find no change or increased susceptibility to mAb neutralization and 
unlikely to find a SP chimera IMC that was more resistant to neutralization by mAbs. 
Surprisingly, we found that the WT IMC was highly susceptible to neutralization by mAb 
697-D (~45% neutralization at 4 μg/mL and ~75% at 100 μg/mL), while the 398.F1 IMC 
didn’t reach above 20% neutralization by mAb 697-D at the highest concentration tested 
(100 μg/mL) (Figure 2.8). This suggests that natural SP variation can impact antigenic 




Figure 2.8. HIV Env signal peptide influences IMC neutralization by some anti-
V2 domain mAbs. Viral neutralization was determined by chimera NL4.3-
SF162envSP virus incubation with serial diluted the anti-V2 mAbs, as well as positive 
and negative controls for 24h prior to the addition of TZM.bl target cells. Infectivity 
was measured 48h later by β-galactosidase activity assay. Preincubation was done with 
(A) anti-V2 mAb 2158, (B) anti-V2 mAb 830A, (C) anti-V2 mAb 697-D, (D) control 
CD4-Ig (positive control) and (C) irrelevant parvovirus B19 mAb 1418 (negative 
control). Percent neutralization was calculated by comparing infectivity of 
mAb/control preincubation and no preincubation conditions for each virus.  
 
Taken together this data shows that the SP alone can impact the neutralization 
profile of IMCs. While no association between the isolate from which the SP was derived 
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and the neutralization profile by anti-V2 mAbs could be identified, we clearly show that 
the natural variation found in some SPs can greatly impact the susceptibility of these IMCs 
to neutralization by these V2 mAbs. We show that natural variation in the SP can increase 
susceptibility of IMCs to some anti-V2 mAb neutralization. We also show that some SP 
variations can also significantly increase resistance to neutralization by V2 mAbs, a 
remarkable finding considering that the SP is not present in the mature Env that coats these 
IMCs.  
 
2.5 Discussion  
 
The HIV-1 Env is heavily glycosylated [8, 53], and alterations to key PNGSs can 
influence its structure, function, and susceptibility to neutralizing antibodies [22, 36, 54]. 
Evidence of a connection between Env glycosylation and HIV transmission has also been 
described [5]. Previous studies have demonstrated that early-replicating Envs tend to 
encode fewer PNGSs and shorter variable regions in which many PNGSs are located [12, 
13]. Additionally, the glycans that decorate the PNGSs of early-replicating Env contain 
greater high-mannose content compared to Envs isolated from chronic replicating viruses 
[14]. Recently, a second signature of transmission has been described that involves the Env 
SP of early-replicating viral isolates [11, 16]. This SP transmission signature has also been 
described in SIV and SHIV transmission studies [17]. The identification of this signature 
suggests that the SP may influence the transmission bottleneck that is established around 
the time of transmission. Understanding the effect of natural variation in the SP coding 
sequence on the Env protein structure and antigenicity is important insofar as Env is the 
major target for neutralizing antibodies. In this report, we show that the SP of the HIV Env 
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protein can impact both the antigenicity of gp120 and the susceptibility to anti-V2 
antibodies. This is the first demonstration that natural variation in the SP of Env can impact 
neutralization susceptibility in IMCs. These findings are remarkable in that the SP of Env 
is not present in the mature Env protein that decorates mature virions.  
The identification of a transmission signature located in the SP of Env by Asmal 
and colleagues [11] implies that the SP is a target of selective pressure during the early 
events of transmission. Previous studies in which the SP of HIV-1 Envs have been altered 
or swapped with SPs from unrelated proteins have been shown to alter the rates of Env 
processing [23-25, 55]. The conclusions from those studies confirm the importance of 
certain key features of SPs, including the charged n-region. In the present study, we used 
the natural variation found in subtype B Envs from two independent patient isolates that 
incorporate the presence or not of the SP transmission signature. We found that the SP can 
significantly influence the glycan profile and antigenicity of gp120. We also found by 
production of infectious molecular clones with chimera SPs that natural variation found in 
SP coding sequences from a range of HIV subtypes can greatly impact the susceptibility to 
viral neutralization by anti-V2 bnAbs. This suggests that the observed high degree of 
sequence variation in SPs can influence Env structure and antigenicity in a manner that has 
not previously been recognized.  
Our findings implicate the SP of Env as a potential regulator of PTMs that influence 
functional characteristics of gp120 associated with transmission. We found that by 
swapping the SP of Envs in a way that either inserted or removed the SP transmission 
signature, the molecular weight of the resulting gp120 was significantly altered, 
predominantly by a modification of the carbohydrate content of gp120. Thus, these data 
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establish a clear connection between natural variations found in the Env SP and the gp120 
carbohydrate profile.  It is noteworthy that a domain that does not appear in the mature 
protein can alter the glycan shield, which plays a key role in immune evasion.   
Env has been shown to bind to and interact with multiple host surface proteins and 
receptors, and affinities for these receptors can change during the course of infection and 
disease progression [56]. One such receptor, believed to be relevant to HIV transmission 
is the C-type lectin receptor DC-SIGN, which is expressed on the surface of dendritic cells 
that survey mucosal tissues [39]. After antigen capture, these DC-SIGN+ dendritic cells 
migrate to secondary lymphoid tissues and present the captured antigen to T-cells [57]. 
DC-SIGN captured HIV has been shown to promote trans-infection of CD4+ T-cells 
through its interaction with viral Env [39]. This capture and presentation of virus particles 
to target cells is believed to play a role in mucosal transmission of HIV. We show that the 
interaction dynamics between DC-SIGN and Env can be altered by variations in the Env 
SP. This result raises the possibility that one of the selective forces associated with 
variation in the SP may involve modulation of affinity for DC-SIGN and other C-type 
lectin receptors involved in transmission. The SP of ebolavirus glycoprotein has been 
implicated as a determinant of DC-SIGN engagement by modulating the incorporation of 
high-mannose carbohydrates into the glycoprotein [58]. These data also raise the potential 
for the SP to impact the binding of other receptors relevant to HIV transmission, like 
integrin α4β7. 
Consistent with the effects of glycans on Env structure [45], we find that variations 
in Env SP can substantially influence the antigenicity of gp120. We probed the two native 
gp120s along with the two SP hybrids with the conformation specific mAbs 17b and A32 
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that preferentially recognize gp120s that adopt a CD4i open conformation. We determined 
that SPs do impact the reactivity of Env with both mAb 17b and A32.  The two gp120s 
with the early-replicating SP reacted more efficiently with these mAbs compared with the 
two gp120s that lacked the early-replicating SP signature. Of note, Envs that react with 
mAbs that recognize the CD4i conformation are associated with greater susceptibility to 
antibody neutralization [59].  
To test the susceptibility to antibody neutralization, we generated replication 
competent chimera IMCs in which the SP had been swapped to naturally occurring isolate 
SP sequences. Because the V2 domain of gp120 contains conserved PNGSs targeted by 
neutralizing mAb and its structure is highly susceptible to altered glycosylation, this panel 
of SP chimera IMCs was subjected to viral neutralization by anti-V2 mAbs. We show that 
there is a range in the effects of SP variation on antibody neutralization. In some cases, a 
SP chimera IMC does not alter susceptibility to a particular anti-V2 mAb while increasing 
susceptibility to another. The finding that our SP chimera IMCs had either unaltered 
neutralization profiles or had increased susceptibility to neutralization was anticipated. In 
many cases, generating mutations or chimera proteins promotes instability in the mature 
protein, leading to greater susceptibility to antibody neutralization. However, we 
hypothesized that it would be unlikely to generate a SP chimera IMC that would 
significantly increase the resistance to an anti-V2 mAb. This, however, was the case for 
one such anti-V2 mAb: some SP chimera IMCs were rendered more resistant to 
neutralization by mAb 830A. This shows that the SP, which is not present in the virion, 
can modulate characteristics of Env that influence susceptibility to neutralization by mAbs, 
including bnAbs. While a connection between characteristics of the isolate from which 
 62 
each SP is derived and the neutralization profile of the resulting chimera IMC are currently 
unknown, the proof-of-concept that natural variation in the SP can regulate neutralization 
sensitivity is powerful.  
That HIV has adapted a mechanism that can modulate shielding of immune 
pressure on a functional protein by chance variation in a non-mature coding sequence is 
intriguing. It appears likely that HIV has taken advantage of the natural SP variation that 
arises through random mutations to counter the selection by host immune pressure for or 
against characteristics that may relate to viral fitness. This mechanism suggests the SP may 
be used as another tool of the virus in the tug-of-war between the host adaptive immune 
response and viral escape. As the infection progresses, immune pressure builds, selecting 
against less shielded variants. This allows increased prevalence of more shielded variants, 
with presumably less transmission-fitness. Minor variants that maintain less shielded Env, 
however, provide the viral swarm with the needed transmission-fitness to pass the infection 
to new recipients.  
It is important to note that the identification of a SP transmission signature at 
position 12 was achieved without any predisposition toward identifying sequences that 
would alter PTMs or antibody neutralization. Additional studies are required to define the 
rules by which SP sequences can influence PTMs insofar as SP sequences hold the 
potential to influence other characteristics of transmission-fitness. 
Finally, these findings support the concept that SP variations can be utilized in the 
production of recombinant proteins to optimize the glycan profile and antigenicity of 
vaccine immunogens. Much work has been done toward producing optimized vaccine 
 63 
antigens that will hopefully elicit broadly neutralizing antibodies [60]. The results 
presented herein provide a new tool that may be useful in that effort.  
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mAbs TARGETING A HELICAL V1V2 CONFORMATION PRESENT ON 










HIV is gut-tropic and the disruption of the GALT during acute/early HIV infection 
plays an important role in HIV pathogenesis and disease progression. However, the basis 
for the gut-tropic nature of acute HIV infection is unknown. Sieve analysis of the RV144 
HIV vaccine trial, the only HIV vaccine trial with moderate efficacy, found that key 
residues of the V2 loop of HIV Env gp120, K169 and I181, were the target of vaccine-induced 
immune pressure and associated with reduced risk of HIV acquisition. The integrin α4β7 is 
a lymphocyte surface receptor that mediates homing to the GALT via its interaction with 
its natural ligand, MAdCAM. The HIV envelope protein gp120 binds α4β7. The binding 
sites for α4β7 on the V2 loop of gp120 are a highly conserved LDV/I motif located at 
positions 179-181 and a cryptic QKE motif at positions 170-172 located 7 residues 
upstream. These binding sites overlap with the RV144 sieve analysis sites. We report here 
using cell-surface expressed α4β7 and a soluble α4β7 heterodimer that the affinity for gp120 
is similar to that of MAdCAM, and that the gp120 V2 loop can mimic a physiological role 
of α4β7 in lymphocyte adhesion. We show that α4β7 antagonists (gp120 V2 loop mimetics 
and anti-α4β7 mAbs) and a specific class of anti-V2 mAbs disrupt this adhesion interaction. 
The V2 mAbs that inhibit the interaction, CH58, CH59 and CAP228-16H, recognize the 
V2 loop of gp120 in a helical, coiled conformation. Interestingly, other V2 mAbs that 
recognize overlapping residues but in the β-barrel conformation found on SOSIP-stabilized 
Env trimers do not inhibit this interaction. We also show that the CH58 recognized helical, 
coiled conformation is present on the surface of infected cells and virions but appears to be 
present on incompletely processed gp120. This data suggests that non-fully processed Env 
presents the V2 in a helical conformation that exposes the α4β7 binding site(s) potentially 
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making a functional role for “non-functional” Env. This data also supports the connection 
between the gut-tropic nature of acute HIV infection and the interaction between α4β7 and 
HIV Env.  
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3.2 Introduction  
 
The gut associated lymphoid tissue (GALT) is the primary target of HIV infection 
and replication, particularly during the first weeks of infection [1, 2]. In the first few days 
of infection, high levels of replication take place in the GALT leading to severe depletion 
of CD4+ T-cells in this compartment [2-4]. The destruction of GALT CD4+ T-cells is 
associated with irreversible damage to the mucosal GALT barrier that is thought to play a 
major role in the chronic immune activation seen in HIV infection [5-7]. Even with 
administration of anti-retroviral therapy (ART) shortly after infection, this damage is not 
reversible [8]. While the early events of HIV infection significantly contribute to GALT 
destruction, much is still unknown about the early seeding of the GALT during acute HIV 
infection.   
Our group and others have shown that recombinant HIV envelope protein (Env) 
binds to and signals through integrin α4β7, a lymphocyte gut homing receptor [9-12]. 
Integrin α4β7 is expressed on the surface of several lymphocyte subsets including naïve and 
memory CD4+ T-cells [13]. Integrin α4β7 is structurally dynamic in that it can adopt at least 
three distinct conformational states, possibly four. Of these conformational states, two are 
extended, and mediate lymphocyte rolling adhesion [14]. The transition between the 
conformations of α4β7 are regulated intracellularly [15]. The normal function of α4β7 in the 
multi-stage rolling adhesion cascade, is the binding to its natural ligands, mucosal 
addressin cellular adhesion molecule 1 (MAdCAM), vascular addressin cellular adhesion 
molecule 1 (VCAM) and the alternatively-spliced III connecting segment (CS) fragment 
of Fibronectin [16]. Integrin α4β7 is the only integrin capable of binding to MAdCAM [17]. 
MAdCAM is expressed on follicular dendritic cells in the GALT [18, 19] as well as on the 
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endothelial cells that line the lumen of the high endotheial venules (HEVs) of the GALT 
and lamina propria of adults [20-22]. The tissue specific expression of MAdCAM and the 
specificity of MAdCAM for α4β7 together define α4β7 as the gut homing receptor.  
 
Figure 3.1. Structure of α4β7 heterodimer and MAdCAM binding motif. (A) 
Ribbon diagram of a human α4β7 heterodimer headpiece (α4: green, β7: blue) (PDB ID: 
3V4P). Ligand binding groove is highlighted by a red arrow, and the SDL is 
highlighted by a green box. (B) Ribbon diagram of the two N-terminal IgSF domains 
of human MAdCAM (PDB ID: 1GSM). The MAdCAM CC’ loop of IgSF domain 1 
is highlighted in the red box and the DE loop of IgSF domain 2 is highlighted in a 
green box. (C) Schematic of three conformations of the cell surface expression of the 
α4β7 heterodimer. The influence of divalent cations (Mg++ and Mn++) on the type of 
adhesion is listed below. 
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While α4β7 is not required for viral entry for HIV [23-25], our findings suggest a 
link between the gut-tropic nature of HIV infection and this interaction. One suggested role 
is as an attachment factor [26]. While the direct role that α4β7 plays in HIV infection is still 
unknown, growing evidence suggests that α4β7 plays a significant role in the pathogenesis 
of HIV. It has been shown that α4β7highCD4+ memory T-cells are preferentially infected and 
depleted early on in both HIV and SIV infection [8, 27]. Additionally, the pre-infection 
frequency of α4β7highCD4+ memory T-cells is correlated with risk of acquisition of SIV in 
a NHP transmission model [28] and is correlated with risk of acquisition and disease 
progression of HIV in prospective cohort of women in Africa [8]. In an NHP low-dose 
intravaginal SIV transmission model, pre-infusion with an anti-α4β7 mAb protected a 
significant proportion of animals from SIV infection and protected the GALT of the 
animals that did become infected [29]. Additionally, anti-α4β7 mAb infusions combined 
with daily ART promoted durable control of viremia in SIV infected animals after all drug 
therapy was terminated [30]. These studies highlight the significant role α4β7 likely plays 
in the gut-tropic nature of SIV and HIV transmission and pathogenesis, and underscores 
the need for greater understanding of the interaction between gp120 and α4β7.  
Our group and others have shown that a tripeptide motif at positions 179-181 (L179, 
D180 and V/I181) of the V2 domain of gp120 plays a major role in the interaction with α4β7 
[9, 10, 12]. The highly conserved LDV/I motif in gp120 is almost identical to the LDT 
motif in MAdCAM, the IDV motif in VCAM and the LDV motif in Fibronectin that are 
critical for binding α4β7. The core aspartic acid in each of these α4β7 ligands coordinates 
with a Mg++ ion that sits in the metal ion dependent adhesion site (MIDAS) of β7, which is 
required for binding [14, 31]. Another, cryptic tripeptide motif involved in the interaction 
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was identified slightly upstream of the LDV/I motif at positions 170-172 (Q170, R171, and 
V172) [12]. These two α4β7 binding motifs are flanked by PNGSs, and removal of these 
sites enhances recombinant gp120 binding to α4β7 [25]. This suggests that glycan 
carbohydrates may impact the interaction although it is not currently known how reduced 
glycans enhance binding. It is possible that glycans could impact the interaction by direct 
steric hinderance or through conformational constraints indirectly imposed by glycans.  
In the context of recombinant, stabilized trimeric Env spikes, cryo-electron 
microscopy and X-ray diffraction analysis show that the V2 region, including positions 
170-181, appears at the apex of the trimer [32-34] and is presented in a β–strand or β–barrel 
conformation [33-38]. In these structures, the LDV/I motif appears to be buried in a way 
that occludes binding of α4β7. Because of this structural occlusion, we hypothesize that 
binding of α4β7 to the V2 must involve an alternative presentation or a rearrangement of 
the binding motifs of V2. However, it is possible that due to the artificial nature of 
recombinant stabilized Env trimers and the fluidity in Env structure, that the α4β7 binding 
site is not entirely occluded from the native trimer spike. 
It has been shown that the V2 of gp120 is structurally polymorphic in that it can 
adopt a number of distinct conformations [39, 40]. In the context of the recombinant 
stabilized trimer, the V2 adopts a conformation where positions 170-181 are partially or 
entirely presented as a β–strand, notably the β–barrel introduced above or a Greek key 
conformation. These structural analyses utilize bnAbs in complex with SOSIP stabilized 
recombinant trimers or scaffold proteins grafted with the V1V2 loop. bnAbs that recognize 
these conformations tend to be broadly neutralizing, glycan dependent, and trimer 
preferring [41, 42]. Because the Env trimer is necessary for viral entry, it is believed that 
 75 
the β–stranded conformation of the V2 is associated with this function. Other structural 
analyses using linear V2 peptides have shown that the V2 can adopt an alternative 
conformation that is helical or coiled. These analyses utilize what are known as V2p 
(peptide) mAbs, which are in general weakly or non- neutralizing and are glycan 
independent, to form complexes with linear V2 peptides [39, 40]. The mechanism by which 
the conformation of the V2 loop is structured, and the role of these alternative 
conformations is not known.    
In this chapter, we characterize the physical interaction involved in the binding and 
adhesion of Env to α4β7 and the conformational intricacies of the V2 for this interaction. 
We reason that such data provide insight into the role of α4β7 in HIV pathogenesis. We 
demonstrate that the V2 loop of gp120 appears to mimic the way in which MAdCAM 
interacts with α4β7. This mimicry may provide HIV a mechanism of gut-tropism which 
provides access to ideally activated target cells and may further the connection between the 
interaction with the gut homing receptor and the GALT damage associated with HIV 
pathogenesis. This brings forward the possibility that drugs that antagonize the interaction 
between MAdCAM and α4β7 (i.e. FDA approved anti-α4β7 mAb, Vedolizumab) could be 
used to antagonize the interaction between HIV Env and α4β7. We show that select anti-V2 
mAbs isolated from vaccine recipients and naturally infected individuals block the 
interaction between α4β7 and HIV Env in a meaningful way. Several of these vaccine-
elicited anti-V2 mAbs have been associated with protection from infection yet are weakly 
neutralizing. These V2p mAbs that block the interaction recognize an alternative form of 
Env not found in the recombinant stabilized Env trimer. Because glycosylation can greatly 
impact the structure and antigenicity of Env gp120, we also sought to characterize the Env 
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epitope that is recognized by these V2p mAbs. We report that this alternative helical/coiled 
conformation of the V2 is present on infected cells and virions and that it may originate 
from incompletely processed Env with reduced glycan processing. This suggests that 
immature or Env processed in a Golgi-independent pathway is incorporated into virions 
and may have an as yet unidentified functional role: facilitating the interaction between 
α4β7 and HIV Env.  
  
3.3 Experimental Procedures and Methods 
 
3.3.1 Cell lines and reagents 
 RPMI8866 cells, a human B lymphoma cell line that constitutively expresses α4β7 
was purchased from Sigma-Aldrich. Cells were maintained in RPMI-1640 (Lonza) 
containing 10% heat inactivated fetal bovine serum (Gibco), 2% penicillin/streptomycin/ 
glutamine (Gemini Bio-Products) and 0.1% retinoic acid (RA). Cells were cultured for a 
minimum of 7 days prior to use in adhesion assays. RA was obtained from Sigma 
Chemical. mAbs CH58, human mAb isolated from an RV144 vaccinated individual, and 
VRC01 were provided by the NIAID AIDS reagent program. CAP228-16H mAb was 
generated in the laboratory of Dr. Lynn Morris (CAPRISA) [43, 44]). The 830A mAb was 
provided by Dr. Susan Zolla-Pazner (Mt. Sinai Medical School) [35]. Cyclic V2 peptides 
with > 90% purity and having an amino-terminal biotin, derived from 92TH023, BG505 
and C06980v0c22 were supplied by JPT Peptide Technologies. Scaffolds V1/V2 
92TH023-1FD6 and V1/V2 92TH023-Tag were constructed, expressed and purified as 
described elsewhere [35]. CHO cell derived A244 gp120 (Lot 26539–1) was provided by 
Global Solutions for Infectious Diseases (San Francisco, CA). Purification employed an 
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anti-gD immunoaffinity resin, followed by both cation and anion exchange 
chromatography steps. Purity was estimated at 97.1%. BG505 SOISP trimer was 
generously provided by Dr. Paolo Lusso, LIR/NIAID. Vedolizumab was obtained from the 
NIH Clinical Center Pharmacy Department. Human integrin α4 mAb 2B4, MAdCAM-Ig, 
soluble α4β7 and α4β1 were obtained from R&D Systems. The LDV mimetic ELN-475772 
was provided by ELAN Pharmaceuticals [45].   
 
3.3.2 Deglycosylation of purified gp120 and gp140 peptides  
 Prior to use purified gp120 and gp140 proteins utilized in the α4β7 adhesion assays 
were first treated with a deglycosylation protocol [46]. Purified proteins were treated with 
500 U of PNGase F (NEB) per 20 μg of protein under non-denaturing conditions (1X 
GlycoBuffer 2 (NEB), 5mM DTT, and water) at 37 ºC for 3 h.  
 
3.3.3 Surface plasmon resonance analysis of α4β7 or anti-V2 loop mAb binding to 
Hu-MAdCAM, gp120 or cyclic V2 peptides  
 Experiments were performed using a Biacore 3000 instrument (GE Life Sciences) 
using CM4 or CM5 sensor chips. The data were evaluated using BIAevaluation 4.1 
software (GE Life Sciences). The chip surface was activated by injecting 35 μl of a 1:1 
mixture of 0.05 M N-hydroxysuccinimide and 0.2 M N-ethyl-N-(dimethylaminopropyl) 
carbodiimide at 5 μl/min. NeutrAvidin, HIV gp120 or Hu-MAdCAM-Ig (R&D Systems) 
at concentrations of 5 μg/ml in 10mM NaOAc, pH 4.5, were immobilized to approximately 
750 resonance units (RU). After the proteins were immobilized to the desired densities, 
unreacted sites on each surface were blocked with 35 μl of 1 M Tris-HCl (pH 8.0). 
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Biotinylated cyclic V2 peptides (1 μg/ml in 20 mM Tris-HCl, pH 8.0) were bound to the 
NeutrAvidin surfaces to densities of approximately 250–300 RU. One surface was 
activated and blocked without ligand to act as a control surface for non-specific binding of 
the soluble ligand. Any binding was subsequently subtracted from the remaining surfaces. 
Running buffer was HBS (pH 7.4), 0.01 mM CaCl2, either 1 mM MgCl2 or MnCl2, 0.005% 
Tween-20, 0.05% soluble carboxymethyl-dextran. Binding experiments were carried out 
at a flow rate of 25 μl/min at 25 ºC. After a 2 min injection, the surface was washed for an 
additional 2 min in running buffer to follow dissociation of the bound ligand from the 
surface. The surfaces were regenerated by multiple injections of 4.5 M MgCl2 at a flow 
rate of 100 μl/min. Inhibition of α4β7 or anti-V2 loop antibodies by linear V2-loop peptides 
was carried out by pre-incubating the proteins with the peptides in running buffer at the 
indicated concentrations for 2 h at room temperature prior to passing them over the 
prepared surfaces as described above.  
 
3.3.4 Kinetic analysis of anti-V2 loop mAbs binding to cyclic V2 peptides  
Antibodies were diluted to the indicated concentrations in running buffer prior to 
being sequentially passed over the surface bound cyclic peptides as described above. The 
resulting sensorgram series were analyzed using the BiaEvaluation 4.1 software (GE Life 
Sciences) and fitted using a 1:1 Langmuir binding model to determine the kinetic rate and 
affinity constants.  
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3.3.5 α4β7 adhesion to MAdCAM, gp120, and cyclic V2 peptides  
The binding of α4β7 expressed by the RPMI8866 cell line to MAdCAM, HIV A244 
gp120, and HIV cyclic V2 peptides in the absence or presence of vedolizumab or 2B4 or 
ELN-475772 were analyzed by an adhesion assay (adapted from KK Peachman et al.) [11]. 
This assay was modified by culturing RPMI8866 cells in media containing 1 μM RA for 
at least 7 days prior to use in adhesion assays. Inclusion of RA increases adhesion to cV2 
peptides, gp120 and MAdCAM [47]. Briefly, triplicate wells of a 96-well flat-bottom 
polypropylene plate (Greiner Bio-One) were coated overnight at 4 ºC with 100 μl of 2 
μg/ml of MAdCAM (R & D Systems) or 100 μl of 2 μg/ml NeutrAvidin or 100 μl of 0.5–
2.0 μg of deglycosylated HIV gp120 diluted in 50mM bicarbonate buffer, pH 9.6. The 
NeutrAvidin-coated plates were then incubated with biotinylated cyclic V2 peptides (5 
μg/ml in bicarbonate buffer) for 1 h at 37 ºC. The solution from the plates was discarded 
and the plates were then blocked with blocking buffer (25 mM Tris, 2.7 mM KCl, 150 mM 
NaCl, 0.5% BSA, 4 mM MnCl2, pH 7.2) for 1 h at 37 ºC. The solution was discarded, and 
plates were manually washed 4 times with blocking buffer. After blocking and washing the 
plate, RPMI8866 cells in a volume of 50 μl/well were pre-incubated for 40 min at 37 ºC 
with sample buffer in the absence or presence of 10 μg/ml of vedolizumab (α4β7 mAb) or 
2B4 (α4 mAb) or ELN-475772 (α4β7/α4β1 dual inhibitor). Plates were then incubated with 
50 μl/well of 2x105 RPMI8866 cells at 37 ºC (5% CO2) for 1 h, washed 5 times with PBS 
followed by the addition of 100 μl of RPMI-1640 containing 1% FBS, 1% 
penicillin/streptomycin/glutamine, 25mM HEPES with 10 μl/well of AlamarBlue dye. 
Fluorescence (excitation at 560 nm and emission at 590 nm) was kinetically measured 
immediately after the addition of the AlamarBlue dye for 8 h.  
 80 
 
3.3.6 Capture of 92TH023 virions by MNPs coated with gp120 mAbs or α4β7 
92TH023 virions were captured with 15 nm magnetic nanoparticles (MNPs) 
coupled to α4β7 or 2G12, CH58, PG9, and 830A mAbs as previously described [48]. 
Briefly, carboxyl-terminated iron oxide nanoparticles (Ocean Nanotech, San Diego) via 
two step carbodiimide reaction were coated with 1 mg of anti-gp120 mAbs or recombinant 
soluble α4β7 according to manufacturer’s protocol. Virus preparations were derived from 
RA activated primary PBMCs infected with an infectious molecular clone derived from 
92TH023, using standard conditions. To capture virions, MNPs coated with mAbs 
(3.9x1012) in 60 μl were incubated with viral preparation (33 ng/ml based on viral p24 
content) for 1 h at 37 ºC. Captured virions were separated on MACS magnetic columns 
attached to an OctoMacs magnet (Miltenyi Biotech), washed 4 times with 600 μl wash 
buffer (0.5% bovine serum albumin, 2 mM EDTA in PBS), eluted in 200 μl PBS, and 
analyzed on Luminex X200 for p24 content using a dynamic immunofluorescent 
cytometric bead assay [49]. In experiments with α4β7-MNPs, virions were incubated and 
washed with complete medium with 1 mM MnCl2.  
 
3.3.7 Inhibition of α4β7 adhesion to gp120 and cyclic V2 peptides by V2 mAbs  
Triplicate wells of a 96-well flat-bottom polypropylene plate (Greiner Bio-One) 
were coated with biotinylated cyclic V2 peptides or deglycosylated gp120 as described 
above. After blocking and washing, plates were incubated with 20–100 μg/ml of the 
designated anti-V2 mAbs in sample buffer (25 mM Tris, 2.7 mM KCl, 150 mM NaCl, 4 
mM MnCl2, 1% FBS, pH 7.2) for 1 h at 37 ºC. RPMI8866 cells were pre-incubated for 40 
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min at 37 ºC with sample buffer. Plates were then incubated with 50 μl/well of 2x105 cells 
at 37 ºC (5% CO2) for 1 h, washed 5 times with PBS, followed by the addition of 100 μl of 
RPMI-1640 containing 1% FBS, 1% penicillin/streptomycin/glutamine, 25 mM HEPES 
and 10 μl/well of AlamarBlue dye (Invitrogen). Following the addition of AlamarBlue dye 
(excitation at 560 nm and emission at 590 nm) fluorescence was measured kinetically for 
a period of 8 h.  
 
3.3.8 α4β7 adhesion to constrained and unconstrained V1V2 92TH023 scaffolds  
92TH023 V1/V2 was cloned into both 1FD6 (constrained) and tag (unconstrained) 
scaffolds. Plates were then coated with 0.5, 1.0, and 2.0 μg of either V1/V2 92TH023 1FD6 
or V1/V2 92TH023 tag scaffolds followed by addition of RPMI8866 cells. The plates were 
washed and 100 μl of media and 10 μl of AlamarBlue dye was added to each well as 
described above. Fluorescence (excitation at 560 nm and emission at 590 nm) was 
measured kinetically after the addition of the AlamarBlue dye.  
 
3.3.9 Surface staining of HIV infected CD4+ T-cells by flow cytometry  
CD4+ T-cells were isolated from healthy donor PBMCs using a negative selection 
isolation kit as prescribed (Stem Cell Technologies). Cells were activated with OKT3, IL-
2 and retinoic acid for 4 days before infection. Cultures were inoculated with infectious 
molecular clones generated using the designated isolate Env sequence (92TH023, CMU06, 
BG505, AA05, and SF162) inserted into an NL4.3 viral backbone. Viral constructs were 
first transfected into 293T cells before a single passage through PBMCs and harvested. 
Infected CD4+ T-cells were washed with PBS with 5% FBS and stained with 1 μg of anti-
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Env mAb (CH58, CH59, or PG9) for 3 h at 4 C. Cells were washed and then stained with 
fluorescently labeled secondary goat anti-human Ab for 30 min at 4C. Samples were then 
washed and fixed in 4% paraformaldehyde, acquired using a BD Canto II flow cytometer 
and analyzed using FlowJo software. 
 
3.4 Results  
 
3.4.1 The affinity of α4β7 for gp120 V2 is similar to its affinity for MAdCAM  
Previous studies have demonstrated the affinity of the specific interaction between 
gp120 and α4β7 in a qualitative way [9-12]. We sought to determine if the interaction 
between gp120 and α4β7 was in apparent mimicry of the interaction between MAdCAM 
and α4β7 by measuring the specific affinities between the two sets of interacting proteins. 
To do so, we carried out an SPR based assay that utilized dextran surfaces coated with 
recombinant Env peptides and soluble α4β7 heterodimer. Soluble α4β7 was passed over 
surfaces coupled with either Env peptides or MAdCAM-Ig fusion protein. Using a 
recombinant gp120 from isolate A244 (subtype A/E) and MAdCAM-Ig in the presence of 
MnCl2-containing buffer, we measured similar specific affinities for α4β7 (KD of 7.140 and 
0.597 nM, respectively) (Figure 3.2). These affinities were found to be generally 
comparable to that of gp120 and soluble CD4 (KD of 22 nM) [50]. We next replaced the 
A244 recombinant gp120 with a cyclic V2 42-amino acid peptide (cV2) derived from the 
92TH023 isolate (subtype A/E). The affinity of this cV2 92TH023 for α4β7 was found to 
be similar to that of the A244 recombinant gp120 (KD of 1.150 nM) (Figure 3.2) suggesting 
that the V2 of gp120 is sufficient to mediate the high affinity interaction between Env and 
α4β7. Since the cV2 peptide does not contain any N-linked glycans or co-purified 
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contaminants, this suggests that the interaction does not require glycans or matrix proteins 
[51]. We also extended this analysis to a cV2 peptide from the C06980v0c22 isolate 
(subtype C) and recombinant gp120 from BG505 (subtype A) isolate (KD of 1.580 and 
0.919 nM, respectively) (Figure 3.2). Together, this data suggests that the interaction 
between HIV Env and α4β7 is highly conserved and has a comparable affinity to that of the 
natural ligand, MAdCAM.  
 
Figure 3.2. Specific affinity of α4β7 for MAdCAM, HIV gp120s and cV2 peptides. 
(A) Sensorgram of increasing concentrations (2-fold) of soluble α4β7 passed over 
surface-immobilized MAdCAM in the presence of 1 mM MnCl2 for 120 sec, followed 
by a 120 sec washout/dissociation phase. Mass of bound α4β7 (y-axis) expressed as 
response units (RU). Affinity expressed as KD. (B) Same as in panel A, with 
immobilized recombinant A244 gp120. (C) Same as in panel A, with immobilized 
recombinant BG505 gp120. (D) Same as in panel A, with immobilized cyclic V2 (cV2) 
92TH023 peptide. (E) Same as in panel A, with immobilized cV2 C06980v0c22 
peptide. Each sensorgram is representative of three independent measurements.  
  
3.4.2 Adhesion of α4β7 to gp120 is inhibited by antagonists of the MAdCAM - α4β7 
interaction 
The similar high affinities of gp120, cV2 peptides, and MAdCAM for α4β7 suggest 
that gp120 is mimicking the way in which MAdCAM interacts with α4β7. Several 
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antagonists of the interaction between MAdCAM and α4β7 have been developed to treat 
inflammatory bowel disease (IBD) by blocking the MAdCAM binding site on α4β7. If the 
interaction between gp120 and α4β7 is mediated by the same mechanism, MAdCAM 
binding antagonists could be used to interrupt gp120 engagement of α4β7.  
To test the ability of these MAdCAM antagonists to inhibit α4β7 adhesion to gp120, 
we performed a slightly modified adhesion assay based on the protocol developed by 
Peachman and colleagues [11]. In this static adhesion assay, retinoic acid activated α4β7-
expressing RPMI8866 cells were incubated with MAdCAM antagonists. Then the cells 
were added to a 96-well plate coated with MAdCAM or Env peptides. After incubation, 
the non-adhered cells were washed away, and adherence was measured by fluorescent 
cellular dye. As expected, the MAdCAM antagonists inhibited adhesion of α4β7-expressing 
cells to MAdCAM coated wells (Figure 3.3). Adhesion was inhibited by an FDA approved 
mAb therapy used to treat IBD, vedolizumab, which inhibits MAdCAM binding by 
targeting the specificity determining loop (SDL) of β7. Adhesion was also inhibited by the 
small molecule mimetic of the LDV motif, ELN-475772, which blocks the interaction by 
binding to key residues in the ligand binding groove of α4β7. We then tested if these 
MAdCAM antagonists could inhibit the adhesion of α4β7 to HIV Env using the cV2 
92TH023 peptide described above in our adhesion assay. We found that the anti-α4 mAb 
2B4, soluble MAdCAM, ELN-475772, and vedolizumab could all inhibit adhesion of α4β7-




Figure 3.3. Antagonists of MAdCAM engagement with α4β7 inhibit adhesion of 
α4β7-expressing cells to cyclic V2 peptides. A representative result of RPMI8866 
cells adhering to immobilized MAdCAM or a cV2 92TH023 peptide in the absence or 
presence of vedolizumab, an LDV mimetic ELN-475772, the anti-α4 specific mAb 
2B4, soluble MAdCAM-Ig, or control human IgG, as indicated. Adhesion was 
determined at OD 590 nm and listed as fluorescence units (y-axis). Background 
fluorescence (BF) of RPMI8866 cell adhesion to blank wells is denoted by a dashed 
line. Adhesion to immobilized MAdCAM serves as a specificity control for α4β7 
adhesion and human IgG is employed as a reagent control. Conditions are run in 
triplicate and error bars indicate standard error of the mean (SEM).  
 
3.4.3 Adhesion of α4β7 is mediated by a reduced glycan form of gp120 v2 
We have previously reported that removal of N-linked glycosylation sites, 
particularly those of the V2, can influence the capacity of α4β7 to mediate binding of gp120 
in a flow cytometric assay [25]. Rao and collogues recently reported that the adhesion of 
recombinant gp120 to α4β7 requires partial de-glycosylation by gentle enzymatic removal 
of N-linked glycans [46].  
To determine the importance of N-linked glycosylation in our functional adhesion 
assay, we used the recombinant gp120 from A244 isolate to test its capacity to mediate 
adhesion of α4β7-expressing cells to a multivalent surface. This gp120 does not require 
modification to mediate binding of α4β7 in our SPR assay shown above. However, as 
suggested above by us and others, we found that gentle de-glycosylation of the A244 gp120 
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was necessary to mediate adhesion of α4β7-expressing cells (Figure 3.4). This dependency 
for glycan trimming is in agreement with our previous work showing that removal of V2 
glycans can increase binding of recombinant gp120 to α4β7 [25].  
  
Figure 3.4. Adhesion of α4β7 to deglycosylated gp120 and recombinant trimer. (A) 
Adhesion of RPMI8866 cells to immobilized A244 gp120. Deglycosylation (DG) of 
gp120 as indicated. (B) Sensorgram of increasing concentrations (2-fold) of soluble 
α4β7 passed over surface-immobilized BG505 gp120 in the presence of 1 mM MnCl2 
for 120 sec, followed by a 120 sec washout/dissociation phase. Mass of bound α4β7 (y-
axis) expressed as response units (RU). (C) Comparison of adhesion of RPMI8866 
cells to BG505 SOSIP vs. cV2 BG505 peptide. The anti-α4 mAb 2B4 is employed as 
a positive control and the gp120 mAb VRC01 is employed as a negative control.  
 
We also evaluated the ability of a SOSIP stabilized recombinant Env trimer from 
the BG505 isolate to mediate adhesion of α4β7-expressing cells. We found that even though 
the recombinant BG505 gp120 can mediate binding to soluble α4β7 in our SPR assay 
(Figure 3.4), the BG505 SOSIP trimer was unable to mediate adhesion of α4β7-expressing 
cells even after gentle de-glycosylation (Figure 3.4). Given that the recombinant BG505 
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gp120 can bind α4β7 but the BG505 trimer cannot mediate adhesion, we hypothesize that 
the conformational constraints on the V2 in the context of the trimer precludes the 
presentation of the α4β7 binding epitope.   
Taken together this data suggests that glycosylation can impact the interaction 
between the V2 and α4β7 in a major way, but structural characteristics also play a role in 
the manner in which the α4β7 binding sites on V2 are presented.  
 
3.4.4 Weakly neutralizing anti-V2 mAbs elicited by vaccination and natural infection 
inhibit gp120-α4β7 adhesion 
The conformation of the V2 domain of gp120 is dynamic and structurally 
heterogeneous in that it can adopt a range of distinct conformations. Because of this, 
portions of the V1V2 loop of gp120 were often removed from recombinant proteins used 
to generate high resolution crystal structures [52, 53]. To obtain the structure of the V1V2 
loop, the V1V2 fragment has been grafted onto scaffolds derived from unrelated proteins. 
These scaffolds stabilize the V1V2 fragment in complex with conformation dependent V2 
mAbs capable of generating high resolution structures. One such scaffold, 1FD6, grafted 
with a V1V2 fragment in complex with the glycan-dependent bnAb PG9 showed that the 
V2 can adopt a β-sheet conformation in a Greek key structure [36]. The same 1FD6/V1V2 
fragment was also complexed with the mAb 830A which showed that the V2 can also adopt 
a similar β-sheet conformation as part of a β-barrel structure [35]. This β-barrel 
conformation is consistent with reported crystal structures of pre-fusion Env trimer spikes 
[33, 34].  
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However, linear V2 peptides, which do not have the same constraints as scaffolded 
fragments, can adopt helical or coiled conformations [54]. This is the case for a linear V2 
peptide in complex with the weakly neutralizing mAb CH58 [55]. This is noteworthy 
because mAb CH58 was isolated from an uninfected immunized individual enrolled in the 
mildly protective RV144 HIV Vaccine Trial. CH58 recognizes an epitope that maps to 
position 168-181 of the V2 loop. This region includes the two RV144 sieve analysis sites 
K169 and I181 which were identified as targets of vaccine elicited immune pressure in the 
RV144 trial. Helix-preferring mAbs have also been isolated from HIV-infected 
individuals. One such mAb, CAP228-16H, recognizes a helix-coil that is strikingly similar 
to that recognized by CH58 [43, 44].  
Therefore, mAbs that recognize the same region of the V2 loop (positions 153-194) 
recognize at least two distinct epitopes: a constrained β-sheet recognized by glycan-
dependent mAbs like PG9 and 830A, and a less constrained helix-coil conformation 
recognized by weakly neutralizing mAbs CH58 and CAP228-16H. While trimeric Env 
spikes, which are involved in viral entry, present a β-sheet conformation of V2 when 
stabilized in recombinant proteins, the function or significance of the helical conformation 
is not yet known. 
To determine if these two groups of mAbs (830A β-sheet versus CH58 helix) can 
inhibit the adhesion of α4β7-expressing cells to V2 peptides, we tested them in the adhesion 
assay described above. We found that the weakly neutralizing mAbs CH58, CH59 and 
CAP228-16H inhibited adhesion by >90% while bnAb 830A failed to inhibit adhesion to 
a detectable level (Figure 3.5). This suggests that the conformation in which the V2 
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mediates α4β7 adhesion is not a constrained β-sheet conformation associated with the 
recombinant Env trimer, rather it is likely an alternative helical conformation. 
  
 
Figure 3.5. The structure of anti-V2 mAbs in complex with V2 peptides, and anti-
V2 mAb inhibition of α4β7 adhesion. (A) Crystal structure of four V2 domain mAbs, 
CH58 (PDB ID: 4HPO), CH59 (PDB ID: 4HPY), 830A (PDB ID: 4YWG), and 
CAP228-16H (PDB ID: 6FY2) in complex with V2 peptides, Only the Fv regions are 
shown with the heavy chain, light chain, and the V2 epitope colored cyan, green, and 
magenta, respectively. B) Amino acid sequence of the V2 domain of 92TH023. Sieve 
residues identified in the RV144 vaccine study are highlighted in red, along with 
schematics of the epitopes of CH58, Mk16C2 and 830A aligned below (with the 
corresponding HIV isolate listed). Residues in contact with each mAb are highlighted 
in magenta and the size of each amino acid is proportional to the contact surface area. 
C) Adhesion of RPMI8866 cells to cV2 92TH023 in the absence or presence of V2 
mAbs: CH58, CH59, CAP228-16H, and 830A. The mAb VRC01 is included as a 
nonspecific mAb control, and the anti-α4 mAb 2B4 is employed as a positive control. 
Adhesion was determined at OD 590 nm and listed as % inhibition in three or more 
independent experiments relative to cV2 92TH023 in the absence of any inhibitor (y-
axis). Error bars indicate SD.  
 
3.4.5 α4β7 adhesion is mediated by an unconstrained form of the gp120 V2 loop 
V2 helix-preferring mAbs inhibit adhesion of α4β7-expressing cells, while V2 
mAbs with overlapping residues but a trimer associated β-sheet epitope do not mediate this 
adhesion (Figure 3.5). Given this, and the failure of BG505 SOSIP trimer to meditate 
adhesion (Figure 3.4), we hypothesized that the Env trimer has underlying conformational 
restrictions that preclude the presentation or accessibility of the α4β7 binding epitope.  
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To determine if the β-sheet conformation of the V2 is compatible with α4β7 
engagement, we grafted the V1V2 fragment of isolate 92TH023 into two separate 
scaffolds. The first scaffold, termed 1FD6, has been shown to present the V1V2 loop in a 
way that biases its conformation towards that of the β-barrel [35]. This V1V2-1FD6 
scaffold is reactive with mAb 830A and bnAb PG9. The second scaffold, termed tags, has 
been shown to present the V1V2 untethered at the C-terminus allowing it to adopt an 
unconstrained, CH58-reactive helix conformation. We found that the 92TH023 V1V2-tags 
showed ~5x greater adhesion than did 92TH023 V1V2-1FD6 which only mediated a low 
level of α4β7 adhesion (Figure 3.6). This data suggests that α4β7 adhesion requires flexibility 
in the V1V2 loop that is precluded in the SOSIP stabilized BG505 trimer. This preclusion 
is likely due to structural constraints by neighboring sequences in the closed trimer. 
 
 
Figure 3.6. Adhesion of α4β7 to V1V2 scaffolds. Comparison of adhesion of 
RPMI8866 cells to V1/V2 92TH023-1FD6 vs. V1/V2 92TH023-tag scaffolds using 
increasing concentrations of each scaffold as indicated. Adhesion was determined by 
OD 590 nm and listed as fluorescence units (y-axis). Conditions were run in triplicate 




3.4.6 The unconstrained, helical conformation that mediates α4β7 adhesion is found 
on incompletely processed gp120, and is present on the surface of infected cells and 
virions 
HIV is unusual in that a significant fraction of expressed Env proteins appear to 
bypass the Golgi on their way to the cell surface [56]. This form of Env, termed ER-Env, 
lacks Golgi-specific modifications. Despite the lack of Golgi processing, ER-Env is still 
transported to the surface of the infected cell and is presumably incorporated into virions. 
While completely processed Env is believed to be required for viral entry, no function has 
been identified for ER-Env. One suggested possible function of ER-Env is immune 
evasion. Data described here and previously show that Env with reduced glycosylation 
mediates increased α4β7 adhesion. ER-Env lacks large, complex glycan modifications. 
Therefore, we hypothesized that ER-Env may have a biased presentation of the V2 loop of 
gp120 that could engage α4β7. To test this, we first probed the surface of CD4+ T-cells 
infected separately with two infectious molecular clones (IMCs) derived from the 
92TH023 and the CMU06 isolate with anti-V2 mAbs. We found that mAbs CH58 and 
CH59 reacted with Env on the surface of 92TH023 and CMU06 (subtype A/E) infected 
CD4+ T-cells (Figure 3.7). This suggests that the unconstrained, helical conformation is 
present on the surface of infected cells. We then sought to determine whether the 
unconstrained, helical conformation was readily presented on ER-Env. To test this, we 
trypsinized infected CD4+ T-cells to remove surface proteins, and then cultured them 
overnight in the absence or presence of Brefeldin A (BreA), an inhibitor of intracellular 
trafficking between the Golgi and ER compartments. Infected cells cultured in media 
containing BreA will likely have an increased proportion of ER-Env because only surface 
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proteins that are processed in a Golgi-independent pathway will make it to the cell surface. 
When we probed cells infected with viruses derived from four isolates (BG505, CMU06, 
SF162 and AA05), we found that the unconstrained, helix epitope recognized by CH58 
was largely resistant to BreA (Figure 3.7). The β-sheet conformation of the Greek key 
structure recognized by the bnAb PG9 was, as expected, absent in the BreA condition. This 
suggests that the helical CH58 epitope is presented on incompletely processed, ER-Env.   
 
Figure 3.7. Helical, coiled conformation of the V2 loop of gp120 on the surface of 
infected cells. (A) Surface staining with mAbs CH58 and CH59 of primary CD4+ T-
cells infected with two isolates of HIV (92TH023 and CMU06; subtype A/E) or not 
infected. (B) Percent of mAb reactive Env on the surface of primary CD4+ T-cells 
separately infected with four HIV isolates. Infected cells were trypsinized followed by 
overnight culture in the absence or presence of Brefeldin A (BreA). The Percent Max 
Env is calculated by normalizing the percent positive for each mAb to its matching 
BreA minus condition. Data shown is compilation of 2 or more experiments for each 
of the four viral isolates (AA05, CMU06, Bal and BG505).  
 
We then sought to determine whether α4β7-reactive Env and/or the helical 
conformation recognized by V2p mAbs that inhibit α4β7 adhesion (i.e. CH58, CH59 and 
CAP228-16H), could be found on the surface of virions. To test this, we employed 
magnetic nanoparticles (MNPs) coated with either α4β7 or V2 mAbs CH58, PG9, and 830A 
to capture 92TH023 virions derived from primary PBMCs isolated from a healthy donor. 
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The mAb 2G12 was employed as a positive control. Viral supernatants were incubated with 
V2 mAb-coated MNPs. After extensive washing, virion capture was measured by a 
Luminex-based p24 detection assay [49]. In three independent experiments CH58, PG9, 
and 2G12 each captured ~5X greater amounts of virus than non-specific IgG. Capture by 
mAb 830A was surprisingly less efficient (~3X over IgG) (Figure 3.8). The ability of mAb 
CH58, which recognizes a helical structure and inhibits V2 adhesion to α4β7, to capture 
virions suggests that these virions may present an α4β7-reactive form of Env. To test this 
directly we incubated virions with α4β7-MNPs in the absence or presence of increasing 
amounts of the α4β7 inhibitor ELN-475772. The α4β7-MNPs captured virus to levels 
comparable to capture by mAbs 2G12, PG9 and CH58. This capture was inhibited by ELN-
475772 in a dose-dependent manner (Figure 3.8). This data shows that 92TH023 virions 
derived from primary PBMCs present the V2 in a way that is reactive with both mAb CH58 
(helical conformation) and α4β7. Remarkably, this capture is comparable to the level of 
capture by mAb 2G12, which has been shown in protein G- and MNP-based virion capture 
assays to capture ~99% of virions in viral supernatants [57, 58]. This suggests that a 




Figure 3.8. Virion capture by V2 mAbs and α4β7 coated nanoparticles. A) Capture 
of 92TH023 virions by MNPs coated with gp120 mAbs including 2G12 (positive 
control) and V2 mAbs PG9, CH58 and 830A. A non-specific Ig was employed as a 
negative control. Virion capture was determined by detection of MNP-bound p24 (Y-
axis). Results from three independent experiments are shown. B) 92TH023 virion 
capture by α4β7-MNPs in the absence or presence of increasing concentrations of ELN-
475772. Results from three independent experiments are shown. Detection of MNP-
captured virus as in panel A. Error bars indicate SEM. Significance measure by 
ANOVA followed by the Tukey multiple comparison test (***p <0.001 and ****p 
<0.0001).  
 
3.4.7 A 15-amino acid linear V2 peptide inhibits binding of α4β7 to gp120  
Liao and colleagues showed that a 15 aa peptide corresponding to residues 168-181 
of the V2 loop adopts a helical structure when complexed with the weakly neutralizing 
mAb CH58 [55]. We investigated whether a similar 15 aa peptide corresponding to the V2 
loop could inhibit the binding of α4β7 to the V2 loop using the SPR binding assay described 
above. Soluble α4β7 was passed over a cV2 92TH023 coated surface in the absence or 
presence of 8 overlapping linear 15 aa peptides that span the V2 loop. These peptides 
correspond to sequences in an HIV-1 subtype B consensus V2 domain (Figure 3.9A). 
Peptide H43 (Q170KEYALFYKLDVVPI184), which closely aligns with the peptide 
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employed by Liao and colleagues, inhibited α4β7-binding by > 90% (Figure 3.9B). This 
peptide includes both the canonical L179 D180 V181 α4β7 binding site and a Q170 K171 E172 
motif that aligns with the Q170R171V172 cryptic α4β7 epitope identified by Cardozo and 
colleagues [12]. The peptides that flank H43, peptide H42 (R166 
DKVQKEYALFYKLD180) containing just the QKE but not the full LDV motif, and 
peptide H44 (A174LFYKLDVVPIDNDN188), containing just the LDV but not the QKE 
motif, do not inhibit binding. This suggests that the 15 aa V2 peptide containing the two 
α4β7 epitopes is sufficient to inhibit the interaction while 15 aa peptides that contain only 
one of the epitopes are not.  
We repeated this analysis but substituted cV2 92TH023 with A244 gp120 and 
obtained a similar result (Figure 3.9C). We then competed mAbs CH58 and CAP228-16H 
with these same peptides (Figure 3.9D and E). Peptides H42 and H43 each partially 
inhibited mAb CH58 binding and strongly inhibited (> 90%) CAP228-16H binding.  This 
data supports the finding that the CH58 and CAP228-16H epitopes overlap with the α4β7 
epitope.  
Taken together these results suggest that inhibition by peptide H43 involves direct 
binding to α4β7. To rule out allosteric inhibition (i.e. peptide H43 binding directly to, and 
altering the conformation of V2), we carried out a similar peptide inhibition assay with 
immobilized MAdCAM and determined that H43 inhibited α4β7 binding to MAdCAM by 
> 90% (Figure 3.9F). This result is best explained by direct competition between the L179-
D180 in peptide H43 and the critical L41-D42 encoded within MAdCAM IgSF domain 1 
(Figure 3.9G). However, we believe it is very likely that other residues in H43 also engage 
α4β7. We conclude that an epitope contained within a linear peptide corresponding to 
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residues 170–181 of V2 binds directly to α4β7. This same region of V2 overlaps the epitopes 
recognized by CH58 and CAP228-16H. 
 
 
Figure 3.9. Inhibition of α4β7 binding to cyclic V2, gp120, and MAdCAM by 15 
aa linear peptides. A) Alignment of the V2 domains of HIV consensus B with the 
eight HIV consensus B 15 aa peptides (H40-H47) used in this study, and the regions 
of V2 recognized by mAbs CH58 and CAP228-16H. B-C) 15 aa peptide inhibition of 
α4β7 binding to cV2 92TH023 and A244 gp120 as measured by SPR. Percent of α4β7 
binding relative to binding in the absence of peptide (defined as 100%) is shown. D-
E) 15 aa peptide inhibition of V2 mAbs, CH58 and CAP228-16H, binding to cV2 
92TH023. Percent mAb binding relative to binding in the absence of peptide is shown 
(y-axis). F) 15 aa peptide inhibition of α4β7 binding to MAdCAM. Percent α4β7 binding 
relative to binding in the absence of peptide is shown. G) Alignment of α4β7 binding 
site in MAdCAM IgSF domain 1, and peptide H43. Conserved LDV/LDT binding 
motifs are boxed in blue.  
 
3.5 Discussion  
 
The lymphocyte gut homing receptor, integrin α4β7, has increasingly been shown 
to play an important role in the transmission and pathogenesis of SIV and HIV [9, 24, 29, 
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30], both gut-tropic viral infections [1-4]. While α4β7 is non-essential for CD4+ T-cell 
infection by HIV in vitro, an antibody that antagonizes the interaction between α4β7 and 
the V2 loop of gp120 can reduce infection, and can substantially affect disease outcome in 
an acute SIV transmission model [29]. When the same antibody was combined with ART, 
SIV infected animals were able to control viremia in a sustained way [30]. The underlying 
mechanism of viral control in this combination therapy study is not known. However, it 
was reported that all of the controlling animals, among other things, generated an anti-V2 
specific antibody response that mapped to the α4β7 epitope. It has been recently 
demonstrated in a cohort of women that α4β7high CD4+ T-cells are preferentially depleted 
from gut tissues as early as Fiebig I/II providing strong evidence that these cells serve as 
prime early targets following transmission [8]. This contributes to the connection between 
HIV’s gut-tropic nature and α4β7-mediated lymphocyte trafficking to the GALT. Weakly 
neutralizing Abs elicited in the RV144 Thailand HIV vaccine trial targeting the V2 loop 
have been implicated as a correlate of reduced risk of HIV acquisition [59-62]. 
Additionally, key residues in the V2 loop have been identified by molecular sieve analysis 
to be the target of vaccine elicited immune pressure [62]. These sieve sites fall around the 
binding epitope of α4β7. Thus far, the mechanism whereby these weakly neutralizing V2p 
Abs might contribute to this effect has been unclear but may include Fc-mediated effector 
functions [39, 63, 64] , or an as yet identified function. 
The Env that is expressed on the surface of an infected cell and subsequently 
incorporated into virions has been shown to be conformationally heterogeneous [65]. 
While the trimeric Env spike is associated with viral entry, a function of non-trimer 
associated Env has yet to be found. Immune evasion has been suggested as a potential role 
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for this seemingly aberrant Env. Env that is expressed on the surface of infected cells has 
been shown to have a second function: stabilizing what is known as a virological synapse 
(VS). Similar to an immunological synapse, a VS is a tight adhesive junction formed 
between an infected cell and an uninfected target cell, across which virus can be transferred 
efficiently. The oligomeric nature and/or maturity level of Env involved in the VS has yet 
to be characterized. 
In the prefusion closed conformation of the Env trimer, the V2 adopts a β–barrel 
structure that is recognized by several bnAbs. The V2 can adopt an alternative 
conformation that is an unconstrained, helical conformation [55]. It is hypothesized that 
this helical conformation is more compatible with the CD4-bound, open conformation of 
gp120 that is somewhat freed from oligomeric constraints. The helical conformation of V2 
is recognized by mAbs elicited by vaccination (CH58, CH59) and natural infection 
(CAP228-16H). The β–barrel conformation of the V2 in the prefusion closed trimer is 
incompatible with reactivity by these mAbs likely due to oligomeric constraints. Here, we 
show that the CH58-reactive helical conformation is present on the surface of infected 
primary cells. We also show that CH58-reactive Env is incorporated into virions. These 
findings demonstrate that the helical conformation of the V2 is present on the surface of 
infected primary cells as well as virions making the epitope a potential target by HIV 
vaccine candidates. The ratio between CH58-reactive Env and mature trimer Env on each 
virion is not known but our data suggests that a significant fraction of virions have at least 
one Env spike presenting the V2 in an unconstrained, helical conformation. 
Because the lack of the helical conformation of V2 in the context of the Env trimer, 
it is hypothesized that the CH58-reactive, helical epitope is present on incompletely 
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processed or seemingly aberrant Env. In the pathway of post-translational processing, 
secreted and membrane-bound proteins are translated into the ER where initial post-
translational modifications like the addition of high mannose glycans occur. After transport 
to the Golgi, subsequent rounds of processing, including modification of high mannose 
glycans into complex carbohydrate crowns, occurs. A fraction of Env that makes it to the 
surface of infected cells appears to lack the processing that takes places in the Golgi, and 
is therefore referred to as ER-Env. The glycosylation profile of Env has been shown to 
impact antigenic and functional characteristics of Env [66, 67]. Reports suggest that there 
is a connection between glycosylation and HIV transmission [68, 69]. Additionally, early-
transmitting viruses are enriched in high-mannose carbohydrate [70]. Because ER-Env is 
also enriched in high-mannose carbohydrate, it is possible that there is a relationship 
between ER-Env and early-transmitting viruses. We show here that the CH58-reactive 
helical epitope is presented on Env that is processed in a Golgi-independent pathway. This 
suggests that the unconstrained, helical conformation of the V2 is associated with ER-Env 
and that ER-Env may play a role in the modestly protective anti-V2 response of the RV144 
trial.  
We have previously shown that the glycan profile of Env can not only impact the 
antigenicity of gp120, but that glycosylation can influence the reactivity of the V2 loop to 
α4β7, in that removal of PNGSs increases binding of α4β7 [25, 71]. Others have shown that 
trimming of glycans can increase the functional adhesion of α4β7-expressing cells to the 
V2. We show here that, indeed, removal of glycans by PNGase F treatment reveals 
increased adhesion of α4β7 to gp120s that without glycan trimming have low adhesion 
capacity in this assay. Taken together, this suggests that there may be steric influences by 
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glycans that can impact the structuring of the V2 that influence binding to α4β7. However, 
it should be noted that not all Envs need to be deglycosylated to mediate α4β7 adhesion. 
Because of the connection between reduced glycosylation (ER-Env) and the 
capacity to bind α4β7, we hypothesized that there may also be a connection between the 
unconstrained, helical conformation of the V2 and α4β7-mediated adhesion. Here, we report 
that of the multiple conformations that the V2 region of gp120 can adopt, α4β7 interacts 
with the V2 that is presented in a manner distinct from that of the closed Env trimer. A 
scaffolded V1V2 that presents an unconstrained form of the V2 mediates high levels of 
α4β7-adhesion, whereas the same V1V2 fragment in an alternate scaffold presented as a β–
barrel structure mediates only minimal adhesion. We show that a select group of V2 mAbs 
belonging to the V2p class inhibits the adhesion of α4β7-expressing cells to the V2 loop of 
gp120. The V2p mAbs that inhibit adhesion (CH58, CH59 and CAP228-16H) recognize a 
helical or coiled conformation of the V2. Our finding that mAbs CH58 and CH59, which 
were derived from RV144 vaccine recipients, blocks V2-mediated adhesion to α4β7 raises 
the possibility that antibody activities distinct from both neutralization and Fc-mediated 
effector functions might contribute to the efficacy of the RV144 HIV vaccine. Supporting 
this concept is that mAb NCI09, which was derived from a macaque administered an 
SIVmac251-based vaccine designed to mimic the RV144 vaccine [72], also blocks V2-
mediated adhesion to α4β7 [47]. As in RV144, reduced risk of infection in animals 
administered this vaccine was correlated with weakly neutralizing anti-V2 antibodies [72]. 
We also show that the way in which α4β7 interacts with the V2 region of gp120 
shares key features with the interaction between α4β7 and its natural ligand, MAdCAM. 
This apparent mimicry may have important implications in HIV pathogenesis, particularly 
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in regard to the role of the gut in the development of HIV disease. It may also impact anti-
V2 loop immune responses in both infected and vaccinated subjects. One consequence of 
this mimicry is that antagonists developed to treat IBD interfere with V2- α4β7 interactions. 
The V2 domain of HIV gp120 varies in both length and sequence identity. Yet we 
find that V2s from three subtypes of HIV retain the capacity to bind to α4β7, suggesting 
that this interaction is a general property across HIV subtypes. Other studies failed to detect 
a specific interaction between α4β7 and gp120 [51, 73]. An explanation for this discrepancy 
likely reflects two variables. First, as our group and others have shown, the addition of 
glycans can reduce the interaction between recombinant gp120 with α4β7 [25, 46]. It is 
likely that excess amounts of complex carbohydrate and sialic acid moieties that are added 
to gp120s expressed in cell lines contribute to this inhibitory effect. Of note, we 
demonstrated that highly purified (> 95%) cyclic V2 loop peptides that lack glycans bind 
α4β7 with high affinity in both SPR-based binding assays and in a cell-based adhesion 
assay. Removal of glycans in order to observe α4β7 reactivity is not an absolute requirement 
for binding insofar as we were able to capture virions derived from primary cells with α4β7 
coated nanoparticles. The second variable that may influence the sensitivity of α4β7 binding 
assays involves the expression level, and state of α4β7 on cell surfaces. Many integrins rely 
on complex avidity effects and clustering in order to engage ligands. It is likely that the 
surface density of α4β7 plays a key role in its interaction with gp120.  
The specific affinity of α4β7 for gp120 is comparable to that of MAdCAM. Among 
the integrins expressed in humans, α4β7 is distinct in its ability to mediate both lymphocyte 
rolling, and firm adhesion, which reflects the highly specialized nature of MAdCAM-α4β7 
interactions. Integrin α4β7 activity is modulated by dynamic changes in the overall structure 
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of the receptor. It is notable that the V2 region of gp120, despite its variable sequence, is 
able to mimic the binding of α4β7 to MAdCAM. Two pieces of evidence support V2 
mimicry of MAdCAM. First, MAdCAM utilizes divalent cations, which coordinate with 
the D42 in MAdCAM and the MIDAS of β7. The V2 depends on divalent cations for α4β7 
binding in the same way that MAdCAM does. Importantly, the conformational state 
(inactive, intermediate or active) of α4β7 is responsive to both intracellular and external 
cues that are linked to cellular signals generated during inflammatory responses [74, 75]. 
The ability of V2 to discriminate between different forms of α4β7 provides a mechanism to 
distinguish between different subsets of lymphocytes, including those with high potential 
to home to GALT. Given the propensity of HIV to replicate in GALT, it is tempting to link 
the preferential infection and depletion of α4β7high CD4+ T cells in the very early stages of 
infection [8, 27, 76], with V2-α4β7 interactions. However, such a link has not yet been 
established. 
The second line of evidence that supports the proposition that V2 mimics the 
binding characteristics of MAdCAM comes from our demonstration that α4β7 antagonists 
that were developed to block binding to MAdCAM, also block binding to V2. Because of 
the increase in incidence and prevalence of IBD [77], considerable efforts have been taken 
to develop effective treatments, including drugs that target α4β7. Detailed structural 
characterizations of both MAdCAM and α4β7 have been employed in the rational design of 
small molecule LDV mimetics [78]. These mimetics bind with precision to the MAdCAM 
binding site on α4β7, which lies within a deep groove formed by the α4-β7 interface [14]. 
By showing that one of these mimetics compete with V2, we conclude that the aliphatic 
amino acid-Asp motif conserved in HIV fit into this groove and engage α4β7 in a way that, 
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at least partially, mimics the L41-D42 encoded in the MAdCAM CC’ loop of IgSF domain 
1 [79, 80]. These results suggest that the carboxy-terminus of V2 and this IgSF domain 1 
CC’ loop can adopt similar conformations. Evidence for the conserved nature of this 
structure comes from the observation that one SIV V2 mAb, ITS03, whose epitope maps 
close to the α4β7 binding site, blocks α4β7 adhesion to V2 and also cross-reacts with an HIV 
subtype A/E V2 [47]. This raises the intriguing possibility that, with additional screening, 
one might identify a V2 mAb that cross-reacts with MAdCAM. Indeed, other regions of 
the HIV envelope have been shown to mimic “self” epitopes [81]. 
How weakly neutralizing antibodies that block V2-mediated adhesion to α4β7 might 
contribute to reduced risk of infection is unknown. We previously reported that the V2 
region of gp120 can deliver cellular signals through α4β7 [9]. In this regard, integrins 
including α4β7 are key components in integrin associated complexes that are able to 
modulate biochemical pathways and reorganize both cell-surface receptors and the actin-
cytoskeleton [74, 82]. In addition, signaling through α4β7 on CD4+ T cells can impact cell 
activation, proliferation and apoptosis [83, 84]. We recently reported that MAdCAM 
costimulation through α4β7 supports HIV replication in α4β7high CD4+ T cells [85]. Whether 
V2 signaling through α4β7 can similarly support HIV replication requires additional 
investigation. Such information will help determine whether this type of signaling could 
facilitate HIV transmission/replication and whether antibodies that interfere with this 
signal can reduce the risk of infection.  
The way in which the V2 region of gp120 engages α4β7 shares key features with the 
way that MAdCAM, a receptor expressed primarily in gut tissues, engages α4β7. One 
consequence of this apparent mimicry is that antagonists developed to treat IBD by 
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interfering with the interaction between MAdCAM and α4β7 also interfere with V2-α4β7 
interactions. These findings suggest that V2 mimicry of MAdCAM in its interactions with 
α4β7 may influence early events in HIV infection and replication in GALT. Thus, further 
investigation of this interaction and its likely role in early HIV infection will aid in our 
efforts to develop effective prevention and therapeutic strategies.  
The nature of the epitope in V2 that engages α4β7 appears to involve a structure that 
is not present in a recombinant trimer designed to mimic the closed trimeric Env spike. 
Antibodies that target this epitope and block V2-α4β7 interactions are not themselves 
broadly neutralizing, although the structure that they recognize is conserved across the HIV 
clades. Because the weakly neutralizing Abs elicited in RV144 inhibit the interaction, it is 
possible that a connection between the V2-α4β7 interaction and the observed protection in 
RV144 exists. As yet, there is no data to suggest that disrupting the V2-α4β7 interaction 
contributed to RV144 vaccine elicited protection. However, this and other data suggest that 
it is possible that protection could be achieved by eliciting a conformationally specific 
antibody response. Inducing conformationally specific antibody responses to the V2 loop 
has already been accomplished using scaffolded V1V2 peptides in rabbits [86, 87]. 
However, much work is needed to determine if such an antibody response inhibits α4β7 
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Chapter 4:  
CONCLUSIONS AND FUTURE DIRECTIONS 
  
 
4.1 Rationale for Studying Genetic Signatures of HIV-1 Transmission  
 
Development of an HIV vaccine that elicits protective immunity has proven 
difficult despite findings that mucosal transmission of HIV is inefficient. One such 
difficulty in development efforts is that such a vaccine will need to elicit immune responses 
to a broad spectrum of diverse circulating HIV isolates. To combat this obstacle, 
researchers have sought to characterize conserved signatures of viral isolates with greater 
transmission potential or fitness. If viruses isolated immediately after transmission or very 
early in infection have a constrained pattern of sequence diversity, designing a vaccine to 
target such signatures would be beneficial in further reducing the efficiency of HIV 
transmission.  
It has long been understood that high genetic diversity of HIV exists in a single 
HIV infected individual during the chronic phase of infection [1]. This is due to a high 
mutation rate of HIV replication machinery and the eventual selective pressure by the host 
immune system. However, sequence diversity is greatly reduced during transmission [2-
5]. Very often one or very few viral isolates establish a productive infection in a recipient. 
This phenomenon is referred to as the genetic bottleneck of HIV transmission. It is reported 
that dissemination of a single variant occurs in 80% of heterosexual, 75% of MSM, and 
approximately 70% of mother-to-child transmission events [6-12]. The rate of infection by 
a single variant in transmission events of injection drug users is not entirely clear. Many 
key questions about the selective pressures and events that surround mucosal transmission 
and the genetic bottleneck that occurs, remain unanswered. Identifying characteristics that 
govern HIV transmission and infection are essential for the development of effective, 
targeted prevention strategies. Ideal vaccine candidates elicit a response that blocks 
 114 
productive infection by targeting viral proteins in a way that disrupts initial infection or 
significantly reduces transmission fitness. In this way, identifying common, conserved 
characteristics of transmitting viral isolates may lead to targets of prevention strategies that 
could impede transmission.  
In these efforts, several groups have compared HIV Env sequences of isolates 
associated with the early stages of infection to isolates associated with the chronic phase 
of infection. The first of such studies identified that transmitting viral isolates encoded 
compact, glycan-restricted Env proteins [13]. This genetic signature involved a reduced 
number of PNGSs and shorter variable loops of gp120 in which many of these PNGSs are 
located. Other studies showed that specific amino acid residues and motifs were the subject 
of selective pressure: selection away from H12 in the signal peptide of Env during the 
chronic phase of HIV/SIV/SHIV infection, selection for I33A55K57N88 at the time of SIV 
transmission, and  selection for A55D57N88 at the time of HIV and SHIV transmission [14-
16]. These studies show that conserved signatures of HIV, SIV and SHIV transmission are 
under strong selective pressure at specific residues, and therefore, transmission is not a 
stochastic event for the diverse swarm of viruses replicating in a donor [17]. 
The field’s efforts to develop a robustly protective vaccine have proven generally 
unsuccessful. To date, there have been over 220 phase I/II/III HIV vaccine trials, only six 
of which have studied efficacy explicitly [18, 19]. Of these efficacy trials, only one has 
indicated a moderate signal of protection: the RV144 Thailand HIV vaccine trial [20]. Even 
with only 31.2% estimated vaccine efficacy, much has been done to determine any 
potential mechanisms associated with reduced risk of HIV acquisition in this trial. These 
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efforts are paramount for identifying correlates of protection in our efforts to optimize a 
protective HIV vaccine.  
However, the identification of immune correlates of reduced acquisition from the 
RV144 trial suggest that an achievable mechanism of protection may not be the vaccine-
elicited immune response that researchers originally intended to induce with this vaccine. 
As described previously in this thesis, only weakly neutralizing antibody responses were 
elicited in RV144 vaccine recipients. Additionally, antibodies targeting the CD4 binding 
site of gp120 or other “super site” targets of bnAbs were not correlated with reduced risk 
of infection. While neutralizing antibodies may have the capacity to protect non-human 
primates (NHPs) from SIV infection, these findings support the notion that improving the 
alternative mechanism of protection that was involved in achieving moderate protection in 
RV144 is an attractive approach. The search for an alternate mechanism is vigorously 
underway.  
Trials involving human subjects where sequence data can be collected from 
matched acute/early isolates and donor isolates are unfortunately sparse. By definition, 
transmitting viral isolates possess characteristics necessary for viral transmission. 
However, without donor sequence data, it is difficult to form conclusions about the 
existence of selective pressure. This precludes the ability to sufficiently and accurately 
detect genetic signatures of transmission in a statistical way. This highlights the importance 
of ongoing discordant couple cohort studies where donor sequence data is available. 
However, these protocols generally, and ethically, provide education and materials that 
reduce the risk of transmission, and therefore reduce the likelihood of a matched 
transmission event from occurring. Overcoming this obstacle may prove futile. While not 
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ideal, one potential solution to the lack of donor matched sequence data is to conduct SIV 
transmission studies with more genetically diverse stock viruses which could provide more 
statistically robust analysis of genetic signatures.  
In chapter 2, we describe characteristics of gp120 that are influenced by one such 
genetic signature of transmission that was identified in HIV subtype B isolates and later 
confirmed in other HIV sequence cohorts, as well as SIV and SHIV transmission studies 
[16]. We show that an overrepresentation of basic amino acids in the SP of HIV Env biases 
the glycosylation pattern of gp120 in a significant way. Several reports have shown that 
the glycosylation pattern of gp120 plays a major role in the structure and function of gp120. 
We find that significant changes to the glycan profile can be modulated by subtle, 
selectable changes in the SP sequence. This modulation does not rely on mature coding 
sequence mutations but rather variation in a portion of the propeptide that is not present in 
the mature protein. We show that these changes to the glycan profile dramatically impact 
gp120 binding by DC-SIGN, a C-type lectin receptor on DCs that is believed to play a role 
early in transmission. We hypothesize that these changes likely impact reactivity to other 
receptors that have gp120 glycan or structural requirements for their binding, potentially 
integrin α4β7. 
We also report that the genetic signature of transmission in the SP of Env also 
impacts the antigenicity of gp120. We report that by swapping the SP of a recombinant 
gp120 from one bearing the signature to one lacking the signature, the resulting gp120 
adopts are more closed structure. This is in agreement with other data suggesting that the 
virus is selecting for a more guarded gp120 during the chronic phase of infection. Escape 
from immune pressure requires HIV to shield receptor/co-receptor binding sites and other 
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neutralizing epitopes of Env. This signature may be highlighting a mechanism by which 
the virus can modulate the shielding of these sites. The biological relevance of such a 
mechanism is significant.  
In the effort to develop vaccine immunogens, the SP of Env is often neglected. 
Many immunogens are produced with a heterologous SP from another human or viral 
protein. This is done with good intentions: to produce large amounts of recombinant 
protein. However, there may be discrepancies in key features of these recombinant 
immunogens and the natural protein of interest. Our data shows that the SP alone can alter 
the structure of recombinant proteins that contain the same mature coding sequence. This 
suggests that the resulting structure of these recombinant immunogens with heterologous 
SPs is likely different than the intended antigenicity. This likely has major impacts on the 
immunogenicity of the recombinant antigens.  
However, the fact that subtle changes in the SP can modulate the antigenicity of 
immunogens highlights a potential tool in vaccine design. By making changes to the SP of 
recombinant immunogens, modifications to the glycan profile and the antigenicity can be 
accomplished while not altering the mature coding sequence. This may allow for the use 
SP variants to modulate the antigenicity of conserved primary amino acid sequences. 
Whether the SP can bias the immune response to an immunogen is worthy of intense 
research focus.  
The vaccine efficacy observed in the RV144 Thailand HIV vaccine trial was not 
great enough to meet the epidemic’s needs. The field has, however, gained powerful 
insights from RV144 into potential mechanisms of protection and correlates of immunity. 
Building upon these findings has proven complex. With additional knowledge gained from 
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studies of genetic signatures of transmission, previously underappreciated links between 
transmission and Env structure can be explored. This thesis research aimed to make 
connections between genetic signatures of transmission and functional aspects of Env that 
are potential targets of the RV144-elicited immune response.   
 
4.2 A Role for 47 in HIV Transmission and Pathogenesis  
 
It has been shown that expression of α4β7 on CD4+ T-cells in linked with cellular 
activation. These α4β7+CD4+ T-cells also express Ki67, CD69 and CCR5 marking them as 
ideally activated target cells for HIV infection. Additionally, α4β7 colocalizes with CD4 
and CCR5 on the cell surface [21]. The coupling of these receptors reasonably implies that 
HIV may utilize α4β7 as an attachment factor and/or marker of highly activated target cells 
that support viral replication. In the context of the genital mucosa, a majority of the CD4+ 
T-cells are not activated and therefore are not ideal targets for productive infection. One 
could consider the possibility that evolutionary pressure has adapted HIV to interact with 
α4β7 as a way to increase the likelihood of a productive infection. In this way, the affinity 
for α4β7 indicates an opportunity for HIV to increase its transmission fitness.  
One way of studying the role of α4β7 in transmission is to antagonize the interaction. 
Passive infusion of a primatized anti-α4β7 mAb did not protect rhesus macaques from a 
single high dose challenge of pathogenic SIVmac239 [22]. However, it did protect the GALT 
from high levels of viral replication. A more physiologically relevant way to evaluate the 
role of α4β7 in SIV transmission would be to conduct a similar experiment with a viral 
inoculum more reflective of natural infection. This was done by infusing the same anti-
α4β7 mAb and challenging the animals weekly with a low dose of pathogenic SIVmac251 
intravaginally [23]. The mAb infusion significantly delayed infection for 6/12 animals 
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while 10/12 control animals were rapidly infected. The anti-α4β7 mAb protected the 
remaining 6/12 rhesus macaques from infection. Of the treated animals that became 
infected, there was significant protection of the CD4+ T-cell population in the GALT. This 
shows that targeting α4β7 reduces mucosal transmission of SIV in macaques.  
Additionally, it has been shown that α4β7 may play a role in the context of acute 
SIV infection. Infusions of an anti-α4β7 mAb given to rhesus macaques infected with 
pathogenic SIVmac239 but suppressed with daily ART lead to sustained virologic control 
even after all therapies were terminated [24]. All of the control animals had viral rebound 
after termination of ART while the mAb-treated animals either had blips in viremia or had 
no viral rebound at all. The treated animals showed significant protection of the GALT 
CD4+ T-cell population. Additionally, 6/6 of the treated animals developed a unique anti-
V2 immune response that only 3/7 control animals developed. This anti-V2 immune 
response is similar to that observed in RV144 vaccine recipients and correlates with 
reduced risk of HIV and SIV acquisition [25-28]. This data suggests that combination 
therapy of ART and anti-α4β7 mAb allows macaques to effectively control viremia without 
the need for further therapy. It also raises questions as to the mechanism(s) by which 
targeting α4β7 can block transmission and reconstitute an immune response that controls 
viremia.   
Although the link between α4β7 expression and highly activated cells that are ideal 
for viral replication seems to provide sufficient basis for HIV to evolve the capacity to 
interact with α4β7, the integrin has several other functions that may provide further selective 
advantage to develop such an interaction. One such function is that α4β7 also holds the 
capacity to serve as a costimulatory receptor [29, 30]. Our group recently provided 
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evidence that MAdCAM stimulation of naïve and memory CD4+ T-cells through α4β7 leads 
to activation and proliferation that supports viral replication [31]. This MAdCAM signaling 
through α4β7 is blocked by the anti-α4β7 mAb that prevents mucosal transmission of SIV 
in the SIV transmission study described above. Considering the mimicry of MAdCAM by 
the V2 loop of gp120 presented in Chapter 3 and our work showing that MAdCAM co-
stimulation leads to activation and proliferation that supports viral replication, it is possible 
that the V2 loop can also provide this costimulatory signal. Studies aiming to address this 
possibility are currently underway. This is one potential mechanism in which targeting α4β7 
reduces SIV transmission and pathogenesis.  
While the mechanism by which HIV and SIV utilize α4β7 in the context of 
transmission and pathogenesis is still under investigation, the importance of α4β7 in HIV 
acquisition and disease progression has recently been studied. Much of the previous work 
described has been done in an in vitro setting or through the use of animal models. 
However, in a prospective natural history study of a cohort of at-risk women, pre-HIV 
infection frequencies of α4β7+CD4+ T-cells were shown to correlate with increased rates of 
HIV acquisition [32]. This association was stronger when infection was caused by an 
isolate containing V2 motifs with a preference for α4β7 binding. Additionally, pre-infection 
frequencies of α4β7+CD4+ T-cells predicted a higher set-point viral load and an increased 
rate of CD4+ T-cell decline. This data shows that α4β7+CD4+ T-cells play a role in HIV 
transmission and disease progression. In the colon of these individuals, α4β7+CD4+ T-cells 
were rapidly depleted within days of infection, and were not recovered even after 24 
months of ART. In contrast, CCR5+CD4+ T-cells were not significantly depleted in the 
colon until Fiebig stage III, and the frequency of these cells in the gut returned to near 
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baseline levels after 6-24 months of ART. These data show directly that α4β7+CD4+ T-cells 
are preferentially infected and irreversibly depleted during acute HIV infection and that the 
pre-infection frequency of these cells correlates with risk of HIV acquisition and disease 
progression. This data confirms our initial report that HIV preferentially infects and 
depletes α4β7+CD4+ T-cells in vitro. It also underscores the implicit connection between 
the gut homing receptor integrin α4β7 and the gut-tropic nature of HIV infection and 
pathogenesis.  
In this thesis, we present data highlighting the mimicry of MAdCAM in the way 
the V2 loop of gp120 interacts with α4β7. Previous work has shown that the interaction 
between the V2 and α4β7 is mediated by a conserved LDV/I motif in the V2 that is similar 
to that of the LDT motif in MAdCAM involved in α4β7 binding [33]. Our group has also 
shown that the functional capacity of α4β7 adhesion is cation-dependent for both MAdCAM 
and V2 binding [34]. Additionally, we show that inhibitors of the MAdCAM-α4β7 
interaction also block the adhesion of V2 to α4β7. This highlights the potential for 
therapeutics designed to disrupt the MAdCAM-α4β7 interaction to also interfere in HIV-
α4β7 interactions. Further investigation into MAdCAM antagonists as potential inhibitors 
of HIV-α4β7 interactions are needed to better our understanding of this mimicry.  
We also show that a select class of V2 mAbs can interfere with the interaction 
between α4β7 and the V2 loop. These antibodies have been isolated from RV144 vaccine 
recipients (mAbs CH58 and CH59) and from natural infection (mAb CAP228-16H). These 
antibodies recognize an epitope that overlaps with not only the α4β7 interaction binding 
sites (Q170K171E172 and L179D180V181) but also the RV144 sieve sites (K169 and I181). This 
class of antibodies recognizes a conformation of the V2 that is absent from the SOSIP 
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stabilized trimer. In the trimer, the V2 adopts a constrained β-barrel or Greek key 
conformation. However, outside the context of the stabilized trimer, the V2 can adopt an 
alternative conformation that is helical or coiled. The mAbs that block α4β7 adhesion to the 
V2 loop recognize a conserved helical conformation of V2. This data suggests that the way 
in which the V2 loop is presented plays a significant role its capacity to bind α4β7. 
Our data shows that the way in which the V2 is presented in the artificially 
stabilized trimer is not compatible with α4β7 binding. However, we show that α4β7-reactive 
Env is incorporated into virions in that magnetic nanoparticles coated with α4β7 are capable 
of capturing a significant fraction of virus from infected supernatants. We show that mAb 
CH58, which inhibits α4β7-V2 interactions, is capable of capturing a significant fraction of 
virions as well. This data shows that the V2 is presented in a way that is α4β7 reactive on 
the surface of virions.    
The connection between the weakly-neutralizing Abs elicited by RV144 and their 
ability to inhibit α4β7 adhesion, suggests a potential connection between the functional 
targets of RV144 mAbs and the observed protection. There exists no evidence that 
disrupting the α4β7 interaction would contribute to protection in the context of a vaccine, 
however data from our group and others suggests that achieving such a response may 
require eliciting antibodies to a specific, alternative conformation of the V2. The proof of 
concept for generating conformationally specific immune responses has been done. 
Immunization of rabbits with alternative V1V2 scaffolded immunogens induced distinct 
conformation-specific Ab responses [35, 36]. Whether these Ab responses inhibit α4β7 
binding or provide protection have yet to be determined. Much work is needed to confirm 
this intriguing hypothesis.  
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4.3 Implications for Post-Translational Processing in Vaccine Immunogen Design 
 
Post-translational modifications can directly and indirectly impact the flexibility 
and availability of gp120 epitopes. This is accomplished by the direct and indirect steric 
influence of glycans on adjacent residues or motifs in close proximity after folding. In 
vaccine design, the structure in which the immunogen adopts is critical to the specificity 
of the immune response elicited. Here we show that a shift in glycan profile can impact the 
antigenicity of mature sequence-identical recombinant proteins. By shifting the glycan 
profile to contain a larger proportion of high mannose glycans, we shift the open-ness of 
the gp120 protein as measured by reactivity to CD4i mAbs. This was accomplished through 
the use of natural variation in the SP of Env. We also show that the SP can influence the 
neutralization profile of viruses, particularly by anti-V2 mAbs. This suggests that the 
glycosylation profile altered by natural variation in the SP can greatly impact the reactivity 
of neutralizing mAbs to gp120, an important finding in the context of vaccine induced 
immunity.  
Much work has been done using recombinant gp120 proteins as immunogens in 
HIV vaccine designs. However, in nearly all of these studies, the recombinant protein is 
generated from a construct that replaces the natural SP of the HIV Env with that of a 
heterologous viral SP or one from other proteins. In fact, the RV144 vaccine trail used the 
A244 gp120 sequence but swapped its natural SP for that of HSV gD protein. The use of 
heterologous SPs for vaccine immunogen production is done, quite often, for the 
generation of large quantities of protein. Unfortunately, as we have shown, the SP plays a 
major role in the antigenicity of recombinant gp120s through altered PTM. 
Immunogenicity studies in mice looking at the impact of SP-induced glycan changes on 
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the immune response are currently underway. Initial observations suggest that the SP can 
influence the antibody response. In these preliminary studies, the magnitude of response 
against a cyclic V2 peptide does not appear to differ. However, the reactivity of sera to 
conformationally biased V1V2 scaffolds does appear to vary. These findings, while 
extremely preliminary, suggest that the SP can impact the immunogenicity of gp120 
proteins. Further work is needed to identify the differences in antibody responses elicited 
by SP chimera immunogens. This work could greatly aid in the design of vaccines by 
adding another tool by which immunogenicity can be modulated.  
Most immunization studies have failed to induce broadly neutralizing Abs or Abs 
that protect from infection. It was surprising to find that the vaccine elicited Ab response 
from RV144 was weakly-neutralizing in the standard neutralization assay. The standard 
neutralization assay protocol involves an hour-long incubation of Abs with pseudoviruses 
before testing neutralization. It is noteworthy that Hioe and colleagues show that a longer 
incubation time (24 h) significantly increases the neutralization capacity of mAbs CH58 
and CH59, particularly to the 92TH023 isolate [37]. The explanation for this observation 
is not currently known. However, one possibility is that these mAbs may have binding 
kinetics (i.e. on/off rates) that require longer exposure to the V2 loop. Additionally, it is 
possible that the V2 conformation that they recognize, is not often presented. It may be that 
gp120, which samples multiple conformations, does not readily adopt the helical 
conformation recognized by these mAbs. It is likely that glycosylation impacts the rate in 
which gp120 adopts alternate conformations and therefore access by broadly or weakly 
neutralizing antibodies.       
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In efforts to induce neutralizing, and theoretically protective, mAbs, much has been 
done using the stabilized Env trimer as an immunogen. Our group and others have provided 
ample evidence that the epitope of gp120 in which α4β7 engages is discontinuous and 
requires flexibility in the way in which it is presented. Because the lack of bnAbs elicited 
in the moderately protective RV144 trial, it is possible that an alternative approach that 
does not rely on a trimer-targeting bnAb response may provide sufficient protection. While 
this suggestion is speculative, a vaccine immunogen intended to induce a 
conformationally-specific Ab response may provide such an alternative mechanism of 
protection [35, 36]. It is noteworthy that the Ab response elicited in RV144 appears to 
recognize a conformation-specific epitope that is absent from the stabilized trimer. In fact, 
the RV144 elicited immune response targeted a conserved helical epitope that is not 
presented on fully formed recombinant trimers. We show here that the form of Env 
recognized by CH58 is incompletely processed ER-Env. We also show that mAb CH58 is 
capable of capturing a significant fraction of virions from infected cell supernatants. This 
shows that while these Abs may not inhibit infection in the field’s current neutralization 
assay, they still have biological relevance and are associated with reduced risk of infection. 
One potential hypothesis for this mystery is that the alternate form of ER-Env that these 
Abs are recognizing may play an underappreciated role in HIV transmission that when 
blocked may provide some level of protection. Efforts to better understand the role of ER-
Env in infection and transmission are needed. Additional studies are needed to determine 
the immunogenicity of such differently processed forms of Env.  
As described in this thesis, CH58-like mAbs recognize an incompletely processed 
form of Env on the surface of infected cells and virions. Crystal structure data shows that 
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these mAbs recognize a helical conformation of the V2 that is presented in an 
unconstrained manner. These CH58-like mAbs inhibit α4β7 binding and we show that α4β7 
itself is capable of capturing virions. Together this data suggests a connection between ER-
Env and α4β7 binding that is relevant to virions and infected cells. Because CH58 is 
associated with the RV144 vaccine trial that exhibited moderate protection, it is alluring to 
hypothesize that that α4β7-reactive ER-Env may play a role in transmission and is therefore 
worthy of incorporation into vaccine design. However, we do not know the precise role 
α4β7-reactive ER-Env in HIV infection, transmission and pathogenesis nor do we know 
how differences in incompletely processed Env impact immunogenicity. Much work is 
needed in the area of α4β7-reactive ER-Env in order to answer these questions.  
 
4.4 Summary and Future Directions 
 
The main goal of this thesis was to study the connections between genetic 
signatures of HIV transmission and critical post-translational processing of HIV Env. To 
answer important questions about these topics we incorporated numerous studies of Env 
spanning sequence variation, glycosylation, structure and function. The initial aim of this 
work was to connect a genetic signature located in the SP of HIV Env to variations in Env 
glycosylation. While others have shown that the SP can impact characteristics of Env 
maturation, these previous studies have made use of heterologous SPs from human and 
insect proteins. No other studies have shown that natural variation found in the SP of Env 
associated with transmission could directly lead to an altered glycosylation profile of 
gp120. We show that not only can natural SP variation influence the glycan profile of 
gp120, but that this change in glycosylation impacts reactivity with the receptor DC-SIGN. 
In addition, we showed that the SP alone could impact the antigenicity of gp120 in a major 
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way. Future work should include looking into the impact of HIV Env SP on binding 
kinetics of other transmission-relevant receptors such as α4β7.  
We have outlined several reasons as to the significance of the influence of the Env 
SP. Biologically, this data suggests that the SP has major influence over the post-
translational processing pathway in which transmembrane and secreted proteins traverse. 
In the context of HIV, this suggests that the virus has evolved a mechanism by which it can 
easily modify the glycan shield in an apparent attempt to mask neutralizing epitopes or 
modulate reactivity to transmission-relevant receptors. Selection by the virus for a direct 
mutation in the coding sequence of the mature protein has a potentially high risk of failure 
and/or structural sacrifice. Many of these mutations will be fatal to the virus; a high 
evolutionary cost. However, the evolutionary cost for a mutation in a region not present in 
the mature protein is significantly lower. In fact, if this mutation slightly modifies Env 
without sacrificing the already proven functionality of the mature protein, the mutation 
would be an evolutionary benefit. That the virus has adapted a method of shifting the glycan 
profile to shield from building immune pressure or modify receptor reactivity without 
altering the coding sequence of mature protein is remarkable. This highlights the 
complexity by which the virus is able to evade clearance by the immune system and 
maintain infectivity.  
The identification of the SP signature was made without bias towards 
characteristics that influence neutralizing epitopes. Remarkably, we find that the SP of Env 
can impact the antigenicity of gp120 through altered glycosylation. We also find that 
natural variation in the SP can alter the neutralization profile of SP chimera viruses, 
particularly by anti-V2 mAbs. Future studies of the impact of natural variation in the SP 
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on neutralization are needed and will provide a better understanding of the way in which 
HIV can modulate key features of Env. Additionally, the SP chimera viruses that we have 
generated have provided us a tool by which to study the impact of the SP on the expression 
of Env. One could presume that if the SP can impact gp120 antigenicity, the SP may also 
impact the proportion of ER-Env versus fully-formed trimer Env that is expressed on the 
surface of infected cells or incorporated into virions. Our SP chimera viruses may aid in 
furthering our understanding of the connection between Env characteristics associated with 
transmission and the SP signature.  
In our efforts to define how post-translational modification impacts the structure of 
gp120, we found that mAbs isolated from RV144 (mAbs CH58) recognize Env that is 
processed in a Golgi-independent pathway. How an antibody response against 
incompletely processed Env could mediate protection is not immediately apparent. 
However, we show that CH58-reactive Env is present on the surface of infected cells and 
the surface of virions from infectious supernatants. While our data shows that a significant 
fraction of virions from viral supernatants contain at least one CH58-reactive Env, the 
significance of ER-Env in the context of cell-free and cell-to-cell spread has not been 
identified. It is currently unknow what proportion of Env on the surface of virions is 
reactive with CH58-like mAbs (i.e. ER-Env versus fully formed trimers). Additionally, it 
is not known what fraction of Env on the surface of an infected cell is reactive with CH58-
like mAbs. Is the proportion of ER-Env similar between infected cells and virions? Does 
the ratio change during the course of a single cell’s infection? Can the SP influence this 
ratio? Does the ratio change during the course of disease progression? These questions are 
important in our understanding of the significance of the helical V2 conformation and what 
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controls its presentation. More investigation is needed into the ratio of CH58-reactive Env 
on the surface of infected cells and virions, and the role that the unconstrained presentation 
of the V2 plays in HIV transmission.  
The answers to the questions above will provide a better understanding of the 
abundance of ER-Env in the context of infected cells and virions. However, the functional 
role of ER-Env is still not well characterized. It has been proposed that ER-Env and other 
aberrant Env expression is a mechanism by which HIV can distract the adaptive immune 
response. It is possible that HIV has developed the ability to express ER-Env as a way to 
increase exposure of non-neutralizing or immunodominant epitopes, thereby distracting 
the immune response from “unwanted”, neutralizing epitopes of the trimer. However, we 
believe that ER-Env plays a more functional role in the spread of HIV. Our group 
hypothesizes that the unconstrained conformation of the V2 that is precluded from the 
stabilized trimer is the conformation that mediates adhesion of α4β7. We have previously 
shown that reduced glycosylation and removal of PNGSs increases binding of gp120 to 
α4β7, suggesting a connection between reduced PTMs and α4β7 reactivity [38]. Data 
presented here and by others suggests that ER-Env is capable of interacting with α4β7. This 
work suggests a further connection between PTM and glycosylation and the unconstrained 
structure in which α4β7 engages. We show that mAb CH58, which recognizes an 
unconstrained helical conformation and inhibits adhesion of α4β7 to the V2 loop, is reactive 
to incompletely processed Env. The mAb CH58 and α4β7 are capable of capturing a 
significant fraction of virions from viral supernatants. These data show that the 
unconstrained conformation of the V2 loop that engages α4β7 is present on the surface of 
virions. The physiologically relevant function of ER-Env is not currently known, although 
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it is unlikely that this form of Env is directly involved in membrane fusion. It is possible 
that one potential role of ER-Env is engagement with α4β7. Further studies are needed to 
confirm this hypothesis. 
It is known that α4β7+CD4+ T-cells play a critical role in HIV transmission and 
pathogenesis. However, our understanding of the precise way in which HIV utilizes α4β7 
is incomplete. Does ER-Env on virions bind α4β7 on CD4+ T-cells as an attachment factor 
to increasing the efficiency of infection of target cells? Does ER-Env on virions activate 
CD4+ T-cells through α4β7 to promote proliferation and viral replication? Does ER-Env on 
infected cells interact with α4β7 on bystander CD4+ T-cells in order to stabilize a virological 
synapse? The answers to these questions will provide a better understanding of the role of 
non-fully-processed Env in HIV’s interaction with α4β7. They will also shine light on the 
broader subject of the role of α4β7 in the spread of infection and transmission of HIV.  
Immediately following the publication of the RV144 vaccine trial, our group was 
asked to determine if the anti-V2 response associated with reduced risk could inhibit α4β7 
binding. At that time, our group, and the field in general, lacked an assay capable of 
answering this question. The assays described in this thesis by our group and others suggest 
that it is now possible to revisit this question. Determining whether the response elicited 
by RV144 targets the α4β7 epitope of V2 specifically and if it is capable of inhibiting the 
binding of α4β7 to the V2 loop is a worthy of pursuit.   
In conclusion, we describe throughout this thesis advances in our understanding of 
the regulation of HIV Env glycosylation and how the conformation in which Env is 
presented is critical for its interaction with integrin α4β7. Our work has shown that the virus 
is capable of fine-tuning the glycan pattern of gp120 through natural variations in the SP 
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of Env that can shield neutralizing epitopes from building immune pressure in the host. We 
also show that an alternate, yet conserved, helical conformation of the V2 is the result of 
incompletely processed Env and is recognized by mAbs associated with protection (mAb 
CH58). This incompletely processed Env is present on the surface of infected cells and is 
also incorporated into virions. These helical-epitope-preferring mAbs are weakly 
neutralizing and inhibit the adhesion of α4β7 to the V2 loop of gp120. These findings 
suggest a larger connection between HIV transmission, the interaction between gp120 and 
α4β7, and the gut-tropic nature of HIV pathogenesis. Much remains to be determined about 
the complete impact of SP variation, the significance of CH58-reactive Env, and the role 
of α4β7+CD4+ T-cells in HIV transmission and pathogenesis. These avenues will broaden 
our understanding of the early events of HIV transmission and the mechanisms by which 
HIV has adapted to overcome selective barriers. These approaches will aid in the 
development of improved HIV prevention and therapeutic strategies needed to combat the 
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